<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5844f950-ed79-43de-a6c4-2233878a9222"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use SAXAGLIPTIN TABLETS safely and effectively.  See full prescribing information for <content styleCode="bold">SAXAGLIPTIN TABLETS</content>.<br/>Â <br/>
      <content styleCode="bold">SAXAGLIPTIN tablets, for oral use</content>
      <br/>Initial U.S. Approval: 2009</title>
   <effectiveTime value="20250228"/>
   <setId root="6e8d8c4f-96eb-4b64-9c8c-4a5448a23a78"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="059295980" root="1.3.6.1.4.1.519.1"/>
            <name>Mylan Pharmaceuticals Inc.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="6192b33f-a8e4-4cea-be6d-7b7a5f67bfb7"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250228"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0378-4705" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Saxagliptin</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>saxagliptin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4N19ON48ZN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="8I7IO46IVQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SAXAGLIPTIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5XDI2TS1EZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 200</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4R4HFI6D95" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 4000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0378-4705-93" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230804"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0378-4705-77" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230804"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA205980" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230804"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">SX1;M</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0378-4706" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Saxagliptin</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>saxagliptin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4N19ON48ZN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="8I7IO46IVQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SAXAGLIPTIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5XDI2TS1EZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 200</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4R4HFI6D95" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 4000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0378-4706-93" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230804"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0378-4706-77" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230804"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA205980" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230804"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">SX2;M</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_5b9a4874-a9bc-423c-85b3-5cd8689fc3cb">
               <id root="98d75dea-5fa5-4ded-8c9b-7552a047fa9e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (<linkHtml href="#ID_ae1d1cd0-c79c-4226-83a8-289de923d7da">1.1</linkHtml>)</paragraph>
                        <paragraph>Limitations of use:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. (<linkHtml href="#ID_e4ad3d84-6749-477a-98d9-7548eb97dac5">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_ae1d1cd0-c79c-4226-83a8-289de923d7da">
                     <id root="ae1d1cd0-c79c-4226-83a8-289de923d7da"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Monotherapy and Combination Therapy </title>
                     <text>
                        <paragraph>Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [<content styleCode="italics">see</content>Â <content styleCode="italics">
                              <linkHtml href="#ID_43e63f5d-9fde-4c5d-8066-5331284d3c9c">Clinical Studies (14)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20230423"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e4ad3d84-6749-477a-98d9-7548eb97dac5">
                     <id root="f438395a-c919-4ecb-a43e-2f0cffa1381d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Limitations of Use </title>
                     <text>
                        <paragraph>Saxagliptin tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_cf008e67-c1e4-49cb-953a-6aad072ef7ec">
               <id root="4d5f8310-47df-4cfc-a5e1-44fd14feb2f1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Recommended dosage is 2.5 mg or 5 mg orally once daily taken regardless of meals. (<linkHtml href="#ID_183d12b3-0d40-419f-86ba-e5d3f57f28ff">2.1</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>Patients with an eGFR &lt; 45 mL/min/1.73 m<sup>2</sup> (moderate or severe renal impairment, or end-stage renal disease): Recommended dosage is 2.5 mg once daily regardless of meals. (<linkHtml href="#ID_089a1453-d2bb-4ef6-bd16-592afb59468a">2.2</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>Assess renal function before starting saxagliptin tablets and periodically thereafter. (<linkHtml href="#ID_089a1453-d2bb-4ef6-bd16-592afb59468a">2.2</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>Limit the dosage of saxagliptin tablets to 2.5 mg daily for patients also taking strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole). (<linkHtml href="#ID_4e83fe0a-9a92-4dde-be1b-daaf9217bddd">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_183d12b3-0d40-419f-86ba-e5d3f57f28ff">
                     <id root="dec7c87c-5af3-4989-951b-2ee8a728d861"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Recommended Dosage </title>
                     <text>
                        <paragraph>The recommended dosage of saxagliptin tablets is 2.5 mg or 5 mg orally once daily taken regardless of meals. Do not cut, crush, or chew saxagliptin tablets.</paragraph>
                        <paragraph>If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_089a1453-d2bb-4ef6-bd16-592afb59468a">
                     <id root="33ff0e93-fbb6-46ee-a934-baf95880608a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Dosage in Patients with Renal Impairment </title>
                     <text>
                        <paragraph>Assess renal function prior to initiation of saxagliptin tablets and then as clinically indicated [<content styleCode="italics">see <linkHtml href="#ID_06d9f3cf-e93b-47dc-b13b-f2493d6c348c">Use in Specific Populations (8.6)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>The recommended dosage of saxagliptin tablets in patients with an eGFR greater than or equal to 45 mL/minute/1.73 m<sup>2</sup> is the same as the recommended dosage in patients with normal renal function [<content styleCode="italics">see <linkHtml href="#ID_183d12b3-0d40-419f-86ba-e5d3f57f28ff">Dosage and Administration (2.1)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>The dosage of saxagliptin tablets is 2.5 mg orally once daily for patients with eGFR &lt; 45 mL/min/1.73 m<sup>2</sup> [which includes a subset of moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis] [<content styleCode="italics">see <linkHtml href="#ID_490b6015-bab0-4788-bdea-d5cce92e2329">Clinical Pharmacology (12.3)</linkHtml> and <linkHtml href="#ID_bf75c661-841c-4a69-8df6-66385f6c3e24">Clinical Studies (14.2)</linkHtml>
                           </content>]. Saxagliptin tablets should be administered following hemodialysis. Saxagliptin tablets have not been studied in patients undergoing peritoneal dialysis.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4e83fe0a-9a92-4dde-be1b-daaf9217bddd">
                     <id root="34900560-a6b8-48ee-9ae7-8de9a063baf5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage Modification with Concomitant Use of Strong CYP3A4/5 Inhibitors </title>
                     <text>
                        <paragraph>The dosage of saxagliptin tablets is 2.5 mg orally once daily when used concomitantly with strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin) [<content styleCode="italics">see <linkHtml href="#ID_99a9906d-2407-433c-a6a1-00c0c0984acf">Drug Interactions (7.1)</linkHtml>
                           </content> and <content styleCode="italics">
                              <linkHtml href="#ID_490b6015-bab0-4788-bdea-d5cce92e2329">Clinical Pharmacology (12.3)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e2e90c77-2039-4d63-91c1-e222a1296e58">
               <id root="e2e90c77-2039-4d63-91c1-e222a1296e58"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Saxagliptin Tablets are available containing 3.075 mg or 6.149 mg of saxagliptin hydrochloride dihydrate equivalent to 2.5 mg or 5 mg of saxagliptin.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>The 2.5 mg tablets are yellow, film-coated, round, unscored tablets imprinted with <content styleCode="bold">SX1</content> over <content styleCode="bold">M </content>in black ink on one side of the tablet and blank on the other side. </item>
                     <item>
                        <caption>â¢</caption>The 5 mg tablets are white to off-white, film-coated, round, unscored tablets imprinted with <content styleCode="bold">SX2</content> over <content styleCode="bold">M </content>in black ink on one side of the tablet and blank on the other side. </item>
                  </list>
               </text>
               <effectiveTime value="20230423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Tablets: 5 mg and 2.5 mg. (<linkHtml href="#ID_e2e90c77-2039-4d63-91c1-e222a1296e58">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_a1bda44a-d76f-44ed-841f-55e59da1d58b">
               <id root="53acec9e-e4c0-4253-8a78-77b170dc18a5"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Saxagliptin tablets are contraindicated in patients with a history of a serious hypersensitivity reaction to saxagliptin or any of the ingredients in saxagliptin tablets. Reactions such as anaphylaxis, angioedema, or exfoliative skin conditions have been reported with saxagliptin tablets [<content styleCode="italics">seeÂ <linkHtml href="#ID_8c98972f-67eb-45e1-87ae-a7840ea32027">Warnings and Precautions (5.4)</linkHtml> and <linkHtml href="#ID_fe77d399-dd08-428d-b303-a763c49833ee">Adverse Reactions (6.2)</linkHtml>
                     </content>].</paragraph>
               </text>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>History of a serious hypersensitivity reaction (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to saxagliptin or any of the ingredients in saxagliptin tablets. (<linkHtml href="#ID_a1bda44a-d76f-44ed-841f-55e59da1d58b">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_c41bebd1-3199-4acd-8bd3-df28955a4e71">
               <id root="14975666-a096-4e4d-97a3-3119df6b7784"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Pancreatitis:</content> There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue saxagliptin tablets. (<linkHtml href="#ID_6fd8cfc7-89d8-4016-bdd4-141f7d5d3b8f">5.1</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Heart Failure:</content> Consider the risks and benefits of saxagliptin tablets in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms. (<linkHtml href="#ID_5e9d776f-8f20-4110-910e-ccb6ef554034">5.2</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Hypoglycemia with Concomitant Use of Insulin or Insulin Secretagogues: </content>Consider a lower dosage of insulin or insulin secretagogue when used in combination with saxagliptin tablets. (<linkHtml href="#ID_e5fc6b8e-d5f7-4aa6-a1c8-bb81dd5f1b30">5.3</linkHtml>)<content styleCode="italics"/>
                           </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Hypersensitivity-Related Events: </content>There have been postmarketing reports of serious hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin conditions. If hypersensitivity reactions occur, discontinue saxagliptin tablets, treat promptly, and monitor until signs and symptoms resolve. (<linkHtml href="#ID_8c98972f-67eb-45e1-87ae-a7840ea32027">5.4</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Arthralgia</content>: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate. (<linkHtml href="#ID_b0ec0aa9-80d4-4a6a-9c30-0807d5ed49c8">5.5</linkHtml>) </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Bullous Pemphigoid:</content> There have been postmarketing reports of bullous pemphigoid requiring hospitalization in patients taking DPP-4 inhibitors. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue saxagliptin tablets. (<linkHtml href="#ID_09a99408-1947-4d2a-9445-3c5aca5a5ba2">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_6fd8cfc7-89d8-4016-bdd4-141f7d5d3b8f">
                     <id root="6fd8cfc7-89d8-4016-bdd4-141f7d5d3b8f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Pancreatitis </title>
                     <text>
                        <paragraph>There have been postmarketing reports of acute pancreatitis in patients taking saxagliptin tablets. In a cardiovascular outcomes trial enrolling participants with established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD (SAVOR trial), cases of definite acute pancreatitis were confirmed in 17 of 8240 (0.2%) patients receiving saxagliptin tablets compared to 9 of 8173 (0.1%) receiving placebo. Preexisting risk factors for pancreatitis were identified in 88% (15/17) of those patients receiving saxagliptin tablets and in 100% (9/9) of those patients receiving placebo.</paragraph>
                        <paragraph>After initiation of saxagliptin tablets, observe patients for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue saxagliptin tablets and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using saxagliptin tablets.</paragraph>
                     </text>
                     <effectiveTime value="20230423"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5e9d776f-8f20-4110-910e-ccb6ef554034">
                     <id root="5137ddf1-a759-40d8-bc78-507fcbf45fed"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Heart Failure </title>
                     <text>
                        <paragraph>In a cardiovascular outcomes trial enrolling participants with established ASCVD or multiple risk factors for ASCVD (SAVOR trial), more patients randomized to saxagliptin tablets (289/8280, 3.5%) were hospitalized for heart failure compared to patients randomized to placebo (228/8212, 2.8%). In a time-to-first-event analysis the risk of hospitalization for heart failure was higher in the saxagliptin tablets group (estimated Hazard Ratio: 1.27; 95% CI: 1.07, 1.51). Patients with a prior history of heart failure and patients with renal impairment had a higher risk for hospitalization for heart failure, irrespective of treatment assignment.</paragraph>
                        <paragraph>Consider the risks and benefits of saxagliptin tablets prior to initiating treatment in patients at a higher risk for heart failure. Observe patients for signs and symptoms of heart failure during therapy. Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of saxagliptin tablets.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e5fc6b8e-d5f7-4aa6-a1c8-bb81dd5f1b30">
                     <id root="af021f30-ec65-465a-a1e2-9092c44cecc9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Hypoglycemia with Concomitant Use of Insulin or Insulin Secretagogues </title>
                     <text>
                        <paragraph>When saxagliptin tablets were used in combination with insulin or an insulin secretagogue, the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with insulin or an insulin secretagogue [<content styleCode="italics">see <linkHtml href="#ID_d41ba9d1-2d70-4edd-9648-8a43b89146ec">Adverse Reactions (6.1)</linkHtml>
                           </content>]. Therefore, a lower dosage of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with saxagliptin tablets [<content styleCode="italics">see <linkHtml href="#ID_43165202-7f3e-44e8-9f12-676c42796f56">Drug Interactions (7.2)</linkHtml>
                           </content>]. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8c98972f-67eb-45e1-87ae-a7840ea32027">
                     <id root="8489c853-d4d6-43de-8a98-ccdf7e600338"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>There have been postmarketing reports of serious hypersensitivity reactions in patients treated with saxagliptin tablets. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with saxagliptin tablets, with some reports occurring after the first dose. </paragraph>
                        <paragraph>If a serious hypersensitivity reaction is suspected, discontinue saxagliptin tablets, assess for other potential causes for the event, and institute alternative treatment for diabetes [<content styleCode="italics">see</content>Â <content styleCode="italics">
                              <linkHtml href="#ID_fe77d399-dd08-428d-b303-a763c49833ee">Adverse Reactions (6.2)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>Use caution in a patient with a history of angioedema to another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with saxagliptin tablets.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b0ec0aa9-80d4-4a6a-9c30-0807d5ed49c8">
                     <id root="49227932-ea4e-488b-a6e0-8470c5ec326a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Severe and Disabling Arthralgia </title>
                     <text>
                        <paragraph>There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_09a99408-1947-4d2a-9445-3c5aca5a5ba2">
                     <id root="59e0d14d-fe98-4524-afd7-25309e7e4068"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Bullous Pemphigoid </title>
                     <text>
                        <paragraph>Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving saxagliptin tablets. If bullous pemphigoid is suspected, saxagliptin tablets should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ab6e71b8-65a6-4553-b710-8c927ced598c">
               <id root="0c38eac2-0510-42bd-a978-9850f3a92689"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following serious adverse reactions are described below or elsewhere in the prescribing information:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Pancreatitis [<content styleCode="italics">see <linkHtml href="#ID_6fd8cfc7-89d8-4016-bdd4-141f7d5d3b8f">Warnings and Precautions (5.1)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>â¢</caption>Heart Failure [<content styleCode="italics">see <linkHtml href="#ID_5e9d776f-8f20-4110-910e-ccb6ef554034">Warnings and Precautions (5.2)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>â¢</caption>Hypoglycemia with Concomitant Use of Insulin or Insulin Secretagogues [<content styleCode="italics">see <linkHtml href="#ID_e5fc6b8e-d5f7-4aa6-a1c8-bb81dd5f1b30">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>â¢</caption>Hypersensitivity Reactions [<content styleCode="italics">see <linkHtml href="#ID_8c98972f-67eb-45e1-87ae-a7840ea32027">Warnings and Precautions (5.4)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>â¢</caption>Severe and disabling arthralgia [<content styleCode="italics">see <linkHtml href="#ID_b0ec0aa9-80d4-4a6a-9c30-0807d5ed49c8">Warnings and Precautions (5.5)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>â¢</caption>Bullous pemphigoid [<content styleCode="italics">see <linkHtml href="#ID_09a99408-1947-4d2a-9445-3c5aca5a5ba2">Warnings and Precautions (5.6)</linkHtml>
                        </content>]</item>
                  </list>
               </text>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Most common adverse reactions (incidence â¥ 5% and more often than placebo) are upper respiratory tract infection, urinary tract infection, and headache. (<linkHtml href="#ID_d41ba9d1-2d70-4edd-9648-8a43b89146ec">6.1</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>Peripheral edema was reported more commonly in patients treated with the combination of saxagliptin tablets and a thiazolidinedione (TZD) than in patients treated with the combination of placebo and TZD. (<linkHtml href="#ID_d41ba9d1-2d70-4edd-9648-8a43b89146ec">6.1</linkHtml>) </item>
                        </list>
                        <paragraph>Â </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Mylan at 1-877-446-3679 (1-877-4-INFO-RX)</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_d41ba9d1-2d70-4edd-9648-8a43b89146ec">
                     <id root="50312918-3db9-4742-8caf-f388dee89e53"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_3c05e73b-5375-4146-8083-54bb8ffb9989">
                           <id root="74dcfdc9-f17a-4c07-af79-e7ce69cc03db"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Adverse Reactions in Placebo-Controlled Trials in Adults with Type 2 Diabetes Mellitus<content styleCode="bold">
                                    <content styleCode="italics"/>
                                 </content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>The data in Table 1 are derived from a pool of 5 placebo-controlled clinical trials [<content styleCode="italics">see <linkHtml href="#ID_43e63f5d-9fde-4c5d-8066-5331284d3c9c">Clinical Studies (14)</linkHtml>
                                 </content>]. These data shown in the table reflect exposure of 882 patients to saxagliptin tablets and a mean duration of exposure to saxagliptin tablets of 21 weeks. The mean age of these patients was 55 years, 1.4% were 75 years of age or older and 48.4% were male. The population was 67.5% White, 4.6% Black or African American, 17.4% Asian, 10.5% other races and 9.8% were of Hispanic or Latino ethnicity. At baseline, the population had type 2 diabetes mellitus for an average of 5.2 years and a mean HbA1c of 8.2%. Baseline estimated renal function was normal or mildly impaired (eGFR â¥ 60 mL/min/1.73 m<sup>2</sup>) in 91% of these patients.</paragraph>
                              <paragraph>Table 1 shows common adverse reactions, excluding hypoglycemia, associated with the use of saxagliptin tablets. These adverse reactions occurred more commonly on saxagliptin tablets than on placebo and occurred in at least 5% of patients treated with saxagliptin tablets.</paragraph>
                              <table width="100%">
                                 <caption>Table 1: Adverse Reactions in Placebo-Controlled Trials<footnote ID="_Ref527017171">The 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following: metformin hydrochloride (HCl), thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue.</footnote>Â Reported in â¥ 5% of Patients Treated with Saxagliptin Tablets 5 mg and More Commonly than in Patients Treated with Placebo</caption>
                                 <col width="37%"/>
                                 <col width="34%"/>
                                 <col width="30%"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Lrule Toprule " valign="top"/>
                                       <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">% of Patients</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Saxagliptin Tablets 5 mg</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">N = 882</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Placebo</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">N = 799</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>Upper respiratory tract infection</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>7.7</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>7.6</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Urinary tract infection</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>6.8</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>6.1</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>Headache</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>6.5</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>5.9</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In patients treated with saxagliptin tablets 2.5 mg, headache (6.5%) was the only adverse reaction reported at a rate â¥ 5% and more commonly than in patients treated with placebo.</paragraph>
                              <paragraph>In the add-on to TZD trial, the incidence of peripheral edema was higher for saxagliptin tablets 5 mg versus placebo (8.1% and 4.3%, respectively). The incidence of peripheral edema for saxagliptin tablets 2.5 mg was 3.1%. None of the reported adverse reactions of peripheral edema resulted in trial drug discontinuation. Rates of peripheral edema for saxagliptin tablets 2.5 mg and saxagliptin tablets 5 mg versus placebo were 3.6% and 2% versus 3% given as monotherapy, 2.1% and 2.1% versus 2.2% given as add-on therapy to metformin HCl, and 2.4% and 1.2% versus 2.2% given as add-on therapy to glyburide.</paragraph>
                              <paragraph>The incidence rate of fractures was 1.0 and 0.6 per 100 patient-years, respectively, for saxagliptin tablets (pooled analysis of 2.5 mg, 5 mg, and 10 mg) and placebo. The 10 mg dosage is not an approved dosage. The incidence rate of fracture events in patients who received saxagliptin tablets did not increase over time. Causality has not been established and nonclinical studies have not demonstrated adverse effects of saxagliptin tablets on bone.</paragraph>
                              <paragraph>An event of thrombocytopenia, consistent with a diagnosis of idiopathic thrombocytopenic purpura, was observed in the clinical program. The relationship of this event to saxagliptin tablets is not known.</paragraph>
                              <paragraph>Discontinuation of therapy due to adverse reactions occurred in 2.2%, 3.3%, and 1.8% of patients receiving saxagliptin tablets 2.5 mg, saxagliptin tablets 5 mg, and placebo, respectively. The most common adverse reactions (reported in at least 2 patients treated with saxagliptin tablets 2.5 mg or at least 2 patients treated with saxagliptin tablets 5 mg) associated with premature discontinuation of therapy included lymphopenia (0.1% and 0.5% versus 0%, respectively), rash (0.2% and 0.3% versus 0.3%), blood creatinine increased (0.3% and 0% versus 0%), and blood creatine phosphokinase increased (0.1% and 0.2% versus 0%). </paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_3ece19c7-81d3-4248-8cec-3f9f75c01077">
                           <id root="7c59851c-538e-42be-978e-1344aaf4f153"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Adverse Reactions with Concomitant Use with Insulin</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>In the add-on to insulin trial [<content styleCode="italics">see <linkHtml href="#ID_4d143056-ea3c-4518-a9e6-575f0134feb9">Clinical Studies (14.1)</linkHtml>
                                 </content>], the incidence of adverse reactions, including serious adverse reactions and discontinuations due to adverse reactions, was similar between saxagliptin tablets and placebo, except for confirmed hypoglycemia [<content styleCode="italics">see <linkHtml href="#ID_d41ba9d1-2d70-4edd-9648-8a43b89146ec">Adverse Reactions (6.1)</linkHtml>
                                 </content>].</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_5e95e880-7540-4da1-987d-06b0c9116a41">
                           <id root="15f782e9-37a1-4492-aef4-5a4f19b9ee44"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Hypoglycemia</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Adverse reactions of hypoglycemia were based on all reports of hypoglycemia. A concurrent glucose measurement was not required or was normal in some patients. Therefore, it is not possible to conclusively determine that all these reports reflect true hypoglycemia.</paragraph>
                              <paragraph>In the add-on to glyburide trial, the overall incidence of reported hypoglycemia was higher for saxagliptin tablets 2.5 mg and saxagliptin tablets 5 mg (13.3% and 14.6%) versus placebo (10.1%). The incidence of confirmed hypoglycemia in this trial, defined as symptoms of hypoglycemia accompanied by a fingerstick glucose value of â¤ 50 mg/dL, was 2.4% and 0.8% for saxagliptin tablets 2.5 mg and saxagliptin tablets 5 mg and 0.7% for placebo [<content styleCode="italics">see <linkHtml href="#ID_e5fc6b8e-d5f7-4aa6-a1c8-bb81dd5f1b30">Warnings and Precautions (5.3)</linkHtml>
                                 </content>]. The incidence of reported hypoglycemia for saxagliptin tablets 2.5 mg and saxagliptin tablets 5 mg versus placebo given as monotherapy was 4% and 5.6% versus 4.1%, respectively, 7.8% and 5.8% versus 5% given as add-on therapy to metformin HCl, and 4.1% and 2.7% versus 3.8% given as add-on therapy to TZD. The incidence of reported hypoglycemia was 3.4% in treatment-naive patients given saxagliptin tablets 5 mg plus metformin HCl and 4% in patients given metformin HCl alone.</paragraph>
                              <paragraph>In the active-controlled trial comparing add-on therapy with saxagliptin tablets 5 mg to glipizide in patients inadequately controlled on metformin HCl alone, the incidence of reported hypoglycemia was 3% (19 events in 13 patients) with saxagliptin tablets 5 mg versus 36.3% (750 events in 156 patients) with glipizide. Confirmed symptomatic hypoglycemia (accompanying fingerstick blood glucose â¤ 50 mg/dL) was reported in none of the saxagliptin tablet-treated patients and in 35 glipizide-treated patients (8.1%) (p &lt; 0.0001).</paragraph>
                              <paragraph>In the add-on to insulin trial, the overall incidence of reported hypoglycemia was 18.4% for saxagliptin tablets 5 mg and 19.9% for placebo. However, the incidence of confirmed symptomatic hypoglycemia (accompanying fingerstick blood glucose â¤ 50 mg/dL) was higher with saxagliptin tablets 5 mg (5.3%) versus placebo (3.3%).</paragraph>
                              <paragraph>In the add-on to metformin HCl plus sulfonylurea trial, the overall incidence of reported hypoglycemia was 10.1% for saxagliptin tablets 5 mg and 6.3% for placebo. Confirmed hypoglycemia was reported in 1.6% of the saxagliptin tablet-treated patients and in none of the placebo-treated patients [<content styleCode="italics">see</content>Â <content styleCode="italics">
                                    <linkHtml href="#ID_e5fc6b8e-d5f7-4aa6-a1c8-bb81dd5f1b30">Warnings and Precautions (5.3)</linkHtml>
                                 </content>].</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_dfa01056-6765-4ec7-8be9-002af7e3102b">
                           <id root="a025f98d-1fd3-41d2-bbf3-fa6ac5703f75"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Hypersensitivity Reactions</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Hypersensitivity reactions, such as urticaria and facial edema in the 5-trial pooled analysis up to Week 24 were reported in 1.5%, 1.5%, and 0.4% of patients who received saxagliptin tablets 2.5 mg, saxagliptin tablets 5 mg, and placebo, respectively. None of these events in patients who received saxagliptin tablets required hospitalization or were reported as life-threatening by the investigators. One saxagliptin tablet-treated patient in this pooled analysis discontinued due to generalized urticaria and facial edema.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_faf44687-ade1-4d41-bf00-fa41e326d483">
                           <id root="dfef2aad-53fe-4825-adbb-42ab55be4de9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Renal Impairment</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>In the SAVOR trial, adverse reactions related to renal impairment, including laboratory changes (i.e., doubling of serum creatinine compared with baseline and serum creatinine &gt; 6 mg/dL), were reported in 5.8% (483/8280) of saxagliptin tablet-treated patients and 5.1% (422/8212) of placebo-treated patients. The most frequently reported adverse reactions included renal impairment (2.1% vs. 1.9%), acute renal failure (1.4% vs. 1.2%), and renal failure (0.8% vs. 0.9%), in the saxagliptin tablets versus placebo groups, respectively. From baseline to the end of treatment, there was a mean decrease in eGFR of 2.5 mL/min/1.73 m<sup>2</sup> for saxagliptin tablet-treated patients and a mean decrease of 2.4 mL/min/1.73 m<sup>2</sup> for placebo-treated patients. More patients randomized to saxagliptin tablets (421/5227, 8.1%) compared to patients randomized to placebo (344/5073, 6.8%) had downward shifts in eGFR from &gt; 50 mL/min/1.73 m<sup>2</sup> (i.e., normal or mild renal impairment) to â¤ 50 mL/min/1.73 m<sup>2</sup> (i.e., moderate or severe renal impairment). The proportions of patients with renal adverse reactions increased with worsening baseline renal function and increased age, regardless of treatment assignment.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_d652ec31-4d94-44ab-a033-88186f463f8a">
                           <id root="7632b564-bb57-4373-94f3-1d17499d24cd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Infections</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>In the unblinded, controlled, clinical trial database for saxagliptin tablets to date, there have been 6 (0.12%) reports of tuberculosis among the 4959 saxagliptin tablet-treated patients (1.1 per 1000 patient-years) compared to no reports of tuberculosis among the 2868 comparator-treated patients. Two of these six cases were confirmed with laboratory testing. The remaining cases had limited information or had presumptive diagnoses of tuberculosis. None of the six cases occurred in the United States or in Western Europe. One case occurred in Canada in a patient originally from Indonesia who had recently visited Indonesia. The duration of treatment with saxagliptin tablets until report of tuberculosis ranged from 144 to 929 days. Post-treatment lymphocyte counts were consistently within the reference range for four cases. One patient had lymphopenia prior to initiation of saxagliptin tablets that remained stable throughout saxagliptin tablet treatment. The final patient had an isolated lymphocyte count below normal approximately four months prior to the report of tuberculosis. There have been no spontaneous reports of tuberculosis associated with saxagliptin tablet use. Causality has not been estimated and there are too few cases to date to determine whether tuberculosis is related to saxagliptin tablet use.</paragraph>
                              <paragraph>There has been one case of a potential opportunistic infection in the unblinded, controlled clinical trial database to date in a saxagliptin tablet-treated patient who developed suspected foodborne fatal salmonella sepsis after approximately 600 days of saxagliptin tablet therapy. There have been no spontaneous reports of opportunistic infections associated with saxagliptin tablet use.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_d2f28b5f-aaa8-4aee-9d48-baf537692320">
                           <id root="ae07ff45-39eb-45fc-a192-005d42074b6f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Vital Signs</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>No clinically meaningful changes in vital signs have been observed in patients treated with saxagliptin tablets.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_c592073b-b6c1-4e51-980a-724c40317d8f">
                           <id root="be491fa9-45b8-4e48-a71f-49693496bd6e"/>
                           <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                           <title>
                              <content styleCode="underline">Laboratory Tests</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_bd0e9719-a4d9-45b3-b903-77bea2ed69fb">
                                 <id root="9211339a-9bed-4a0e-b093-306916d283b0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Absolute Lymphocyte Counts </title>
                                 <text>
                                    <paragraph>There was a dose-related mean decrease in absolute lymphocyte count observed with saxagliptin tablets. From a baseline mean absolute lymphocyte count of approximately 2200 cells/microL, mean decreases of approximately 100 and 120 cells/microL with saxagliptin tablets 5 mg and 10 mg, respectively, relative to placebo were observed at 24 weeks in a pooled analysis of five placebo-controlled clinical trials. Similar effects were observed when saxagliptin tablets 5 mg were given in initial combination with metformin HCl compared to metformin HCl alone. There was no difference observed for saxagliptin tablets 2.5 mg relative to placebo. The proportion of patients who were reported to have a lymphocyte count â¤ 750 cells/microL was 0.5%, 1.5%, 1.4%, and 0.4% in the saxagliptin tablets 2.5 mg, 5 mg, 10 mg, and placebo groups, respectively. In most patients, recurrence was not observed with repeated exposure to saxagliptin tablets although some patients had recurrent decreases upon rechallenge that led to discontinuation of saxagliptin tablets. The decreases in lymphocyte count were not associated with clinically relevant adverse reactions. The 10 mg dosage is not an approved dosage.</paragraph>
                                    <paragraph>In the SAVOR trial mean decreases of approximately 84 cells/microL with saxagliptin tablets relative to placebo was observed. The proportion of patients who experienced a decrease in lymphocyte counts to a count of â¤ 750 cells/microL was 1.6% (136/8280) and 1.0% (78/8212) on saxagliptin tablets and placebo, respectively.</paragraph>
                                    <paragraph>The clinical significance of this decrease in lymphocyte count relative to placebo is not known. When clinically indicated, such as in settings of unusual or prolonged infection, lymphocyte count should be measured. The effect of saxagliptin tablets on lymphocyte counts in patients with lymphocyte abnormalities (e.g., human immunodeficiency virus) is unknown.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_fe77d399-dd08-428d-b303-a763c49833ee">
                     <id root="709a5c84-deb5-4541-b976-a99a719b9a37"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2	Postmarketing Experience </title>
                     <text>
                        <paragraph>Additional adverse reactions have been identified during post-approval use of saxagliptin tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Gastrointestinal Disorders:</content> Pancreatitis</item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Immune System Disorders:</content> Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions</item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> Rhabdomyolysis, Severe and disabling arthralgia</item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> Bullous pemphigoid</item>
                        </list>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7534c5a0-b52b-44cf-aaf7-11fbcd89bc31">
               <id root="fa271767-92d6-4e57-85e0-c9bdcec08a3e"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Strong CYP3A4/5 inhibitors (e.g., ketoconazole):</content> Coadministration with saxagliptin tablets significantly increases saxagliptin concentrations. Limit saxagliptin tablets dosage to 2.5 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (<linkHtml href="#ID_99a9906d-2407-433c-a6a1-00c0c0984acf">7.1</linkHtml>)</item>
                        </list>
                        <paragraph>Â </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_99a9906d-2407-433c-a6a1-00c0c0984acf">
                     <id root="87fbf819-586c-4a40-80d8-c6d86382624a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Strong Inhibitors of CYP3A4/5 Enzymes </title>
                     <text>
                        <paragraph>Ketoconazole significantly increased saxagliptin exposure. Similar significant increases in plasma concentrations of saxagliptin are anticipated with other strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). The dosage of saxagliptin tablets should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor [<content styleCode="italics">seeÂ <linkHtml href="#ID_4e83fe0a-9a92-4dde-be1b-daaf9217bddd">Dosage and Administration (2.3)</linkHtml> and <linkHtml href="#ID_490b6015-bab0-4788-bdea-d5cce92e2329">Clinical Pharmacology (12.3)</linkHtml>
                           </content>]. </paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_43165202-7f3e-44e8-9f12-676c42796f56">
                     <id root="1d82ae81-6548-442c-90b1-6db68b3c685f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Insulin or Insulin Secretagogues </title>
                     <text>
                        <paragraph>Insulin and insulin secretagogues are known to cause hypoglycemia. Concomitant use of saxagliptin tablets with insulin or an insulin secretagogue may require lower dosages of insulin or the insulin secretagogue to reduce the risk of hypoglycemia [<content styleCode="italics">see <linkHtml href="#ID_e5fc6b8e-d5f7-4aa6-a1c8-bb81dd5f1b30">Warnings and Precautions (5.3)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_21cbf73c-e89c-4c60-b4f8-69e012078565">
               <id root="d8cef126-4276-49de-8011-ea585919dd07"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250228"/>
               <component>
                  <section ID="ID_3ccfc094-0dbb-48c2-b428-cf27d30a4b19">
                     <id root="51c353f8-635c-4a83-97a4-439f1ae84da3"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_0d9b6bc8-15cc-4789-b2ba-6abcd3236f62">
                           <id root="67b64603-b473-4c73-9835-f3d0364a90e7"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Limited data with saxagliptin tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriages. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [<content styleCode="italics">see <linkHtml href="#ID_c5ec8b43-1d05-4e14-bfd8-5161e86ae06a">Clinical Considerations</linkHtml>
                                 </content>].</paragraph>
                              <paragraph>No adverse developmental effects independent of maternal toxicity were observed when saxagliptin was administered to pregnant rats and rabbits during the period of organogenesis and in pregnant and lactating rats during the pre- and postnatal period [<content styleCode="italics">see <linkHtml href="#ID_be6aad11-8c08-4c1f-b169-d76ccb4976ad">Data</linkHtml>
                                 </content>].</paragraph>
                              <paragraph>The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes with an HbA1c greater than 7 and has been reported to be as high as 20 to 25% in women with an HbA1c greater than 10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_c5ec8b43-1d05-4e14-bfd8-5161e86ae06a">
                           <id root="389e3f3e-7a18-4a36-a825-901ef74b8012"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Clinical Considerations</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_2c442897-e4e5-4ba4-9cd5-476b955e7b0d">
                                 <id root="c81c8adf-f201-435a-b4f1-b70b13e843a7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Disease-associated maternal and/or embryo/fetal risk </title>
                                 <text>
                                    <paragraph>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, still birth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_be6aad11-8c08-4c1f-b169-d76ccb4976ad">
                           <id root="ae84cc9b-c8bb-4206-9f1d-28e0d2190219"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_a6aaf258-9f30-4df4-b31b-2efa1732132a">
                                 <id root="a6aaf258-9f30-4df4-b31b-2efa1732132a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Animal Data </title>
                                 <text>
                                    <paragraph>In embryo-fetal development studies, saxagliptin was administered to pregnant rats and rabbits during the period of organogenesis, corresponding to the first trimester of human pregnancy. No adverse developmental effects were observed in either species at exposures 1503- and 152-times the 5 mg clinical dose in rats and rabbits, respectively, based on AUC. Saxagliptin crosses the placenta into the fetus following dosing in pregnant rats.</paragraph>
                                    <paragraph>In a prenatal and postnatal development study, no adverse developmental effects were observed in maternal rats administered saxagliptin from gestation day 6 through lactation day 21 at exposures up to 470-times the 5 mg clinical dose, based on AUC. </paragraph>
                                 </text>
                                 <effectiveTime value="20230423"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_34bd5dc6-5131-4d08-89af-7b0152e6a643">
                     <id root="a67a18dc-82ca-40fe-9055-c9374c0393e0"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_a2f0b499-dd3b-4b39-a425-5d79cddabfce">
                           <id root="5acdf2e9-d6fb-405b-bcca-7ce40e1f212b"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>There is no information regarding the presence of saxagliptin in human milk, the effects on the breastfed infant, or the effects on milk production.</paragraph>
                              <paragraph>Saxagliptin is present in the milk of lactating rats [<content styleCode="italics">see <linkHtml href="#ID_174cb545-f494-49bb-b68b-34dc1965bde3">Data</linkHtml>
                                 </content>]. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for saxagliptin tablets and any potential adverse effects on the breastfed infant from saxagliptin tablets or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_174cb545-f494-49bb-b68b-34dc1965bde3">
                           <id root="90b9a11d-fd2c-410a-8e0e-18cec8656d0c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Saxagliptin is secreted in the milk of lactating rats at approximately a 1:1 ratio with plasma drug concentrations. </paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_dcce789e-4db1-47c2-9d60-c359d0f5642c">
                     <id root="0a32bfdb-5850-43d1-9141-0e5e1759bf92"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of saxagliptin tablets as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus have not been established in pediatric patients.</paragraph>
                        <paragraph>Effectiveness of saxagliptin tablets was not demonstrated in a 26-week, placebo-controlled, double-blind randomized clinical trial with a 26-week safety extension (NCT03199053) in 164 pediatric patients aged 10 to 17 years with inadequately controlled type 2 diabetes mellitus.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_194d6384-80e6-480d-b77f-19f0848dc028">
                     <id root="b23042e3-cca1-412d-ab63-8d8480bc779d"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>In the seven, double-blind, controlled clinical safety and efficacy trials of saxagliptin tablets, a total of 4751 (42.0%) of the 11301 patients randomized to saxagliptin tablets were 65 years and over, and 1210 (10.7%) were 75 years and over. No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger adult patients.</paragraph>
                        <paragraph>Saxagliptin and its active metabolite are eliminated in part by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly based on renal function [<content styleCode="italics">seeÂ <linkHtml href="#ID_089a1453-d2bb-4ef6-bd16-592afb59468a">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#ID_490b6015-bab0-4788-bdea-d5cce92e2329">Clinical Pharmacology (12.3)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_06d9f3cf-e93b-47dc-b13b-f2493d6c348c">
                     <id root="a87985c6-2575-48af-a8a9-c7686e07b9a9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Renal Impairment </title>
                     <text>
                        <paragraph>In a 12-week randomized placebo-controlled trial, saxagliptin tablets 2.5 mg were administered orally to 85 patients with moderate (n = 48) or severe (n = 18) renal impairment or end-stage renal disease (ESRD) (n = 19) [<content styleCode="italics">see <linkHtml href="#ID_43e63f5d-9fde-4c5d-8066-5331284d3c9c">Clinical Studies (14)</linkHtml>
                           </content>]. The incidence of adverse events, including serious adverse events and discontinuations due to adverse events, was similar between saxagliptin tablets and placebo. The overall incidence of reported hypoglycemia was 20% among patients treated with saxagliptin tablets 2.5 mg and 22% among patients treated with placebo. Four saxagliptin tablet-treated patients (4.7%) and three placebo-treated patients (3.5%) reported at least one episode of confirmed symptomatic hypoglycemia (accompanying fingerstick glucose â¤ 50 mg/dL).</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_56b581b6-f841-471c-a948-97225907fd15">
               <id root="962407a7-a320-4d9e-8c37-bb84fc8c2206"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>In a controlled clinical trial, once-daily, orally-administered saxagliptin tablets in healthy patients at doses up to 400 mg daily for 2 weeks (80-times the MRHD) had no dose-related clinical adverse reactions and no clinically meaningful effect on QTc interval or heart rate.</paragraph>
                  <paragraph>In the event of an overdose, initiate appropriate supportive treatment as dictated by the patientâs clinical status. Saxagliptin and its active metabolite are removed by hemodialysis (23% of dose over 4 hours). Contact the Poison Help Line, (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250228"/>
            </section>
         </component>
         <component>
            <section ID="ID_040bfa4e-ca5d-4c02-8657-e988f88f7538">
               <id root="21c5e410-498a-467c-9b40-fa215eae658c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Saxagliptin is an orally-active inhibitor of the DPP-4 enzyme.</paragraph>
                  <paragraph>Saxagliptin hydrochloride dihydrate is described chemically as (1S,3S,5S)-2-[(2S)-Amino-(3-hydroxytricyclo [3.3.1.1<sup>3,7</sup>]dec-1-yl)acetyl]-2-azabicyclo[3.1.0] hexane-3-carbonitrile hydrochloride dihydrate or (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile hydrochloride dihydrate. The empirical formula is C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>â¢HClâ¢2H<sub>2</sub>O and the molecular weight is 387.92. The structural formula is:</paragraph>
                  <renderMultiMedia ID="id-489015552" referencedObject="a7d8f9e1-1058-4b91-ae36-43be6da1b816"/>
                  <paragraph>Saxagliptin hydrochloride dihydrate is a white to off-white, non-hygroscopic, crystalline powder. It is sparingly soluble in water at 24Â°C Â± 3Â°C, slightly soluble in ethyl acetate, and soluble in methanol, ethanol, isopropyl alcohol, acetonitrile, acetone, and polyethylene glycol 400 (PEG 400).</paragraph>
                  <paragraph>Each film-coated tablet of saxagliptin for oral use contains either 3.075 mg saxagliptin hydrochloride dihydrate equivalent to 2.5 mg saxagliptin or 6.149 mg saxagliptin hydrochloride dihydrate equivalent to 5 mg saxagliptin and the following inactive ingredients: croscarmellose sodium, hydrochloric acid, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium hydroxide, talc and titanium dioxide. The 2.5 mg tablets also contain yellow iron oxide. The imprinting ink contains ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze.</paragraph>
               </text>
               <effectiveTime value="20250228"/>
               <component>
                  <observationMedia ID="a7d8f9e1-1058-4b91-ae36-43be6da1b816">
                     <text>Saxagliptin Hydrochloride Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6718b66b-8a83-41d4-8333-9cee1a8aeafd">
               <id root="57d94524-1dbe-4ede-80bd-e358c29de037"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250228"/>
               <component>
                  <section ID="ID_55092ba6-6991-4038-ab15-a7711c82eca4">
                     <id root="442b9267-9659-4866-80a8-3ec8eaddfca1"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 diabetes mellitus, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is preserved. Saxagliptin is a competitive DPP-4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c42c37fb-5451-4e10-9a24-12aa56b440a1">
                     <id root="13c2c0de-2d26-45cf-97a3-72c9ac10a814"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>In patients with type 2 diabetes mellitus, administration of saxagliptin tablets inhibits DPP-4 enzyme activity for a 24-hour period. After an oral glucose load or a meal, this DPP-4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active GLP-1 and GIP, decreased glucagon concentrations, and increased glucose-dependent insulin secretion from pancreatic beta cells. The rise in insulin and decrease in glucagon were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_d973fdc1-8a02-4aea-b61d-33ba47d4b168">
                           <id root="963822c6-f5c5-43c1-92b7-fe1da1a3ce8c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Cardiac Electrophysiology</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>In a randomized, double-blind, placebo-controlled, 4-way crossover, active comparator trial using moxifloxacin in 40 healthy subjects, saxagliptin tablets were not associated with clinically meaningful prolongation of the QTc interval or heart rate at daily doses up to 40 mg (8-times the MRHD).</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_490b6015-bab0-4788-bdea-d5cce92e2329">
                     <id root="0a4b8268-3f51-4880-b514-f367faf09d7b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>The pharmacokinetics of saxagliptin and its active metabolite, 5-hydroxy saxagliptin were similar in healthy subjects and in patients with type 2 diabetes mellitus. The C<sub>max</sub> and AUC values of saxagliptin and its active metabolite increased proportionally in the 2.5 to 400 mg dose range. Following a 5 mg single oral dose of saxagliptin to healthy subjects, the mean plasma AUC values for saxagliptin and its active metabolite were 78 ngâ¢h/mL and 214 ngâ¢h/mL, respectively. The corresponding plasma C<sub>max</sub> values were 24 ng/mL and 47 ng/mL, respectively. The average variability (%CV) for AUC and C<sub>max</sub> for both saxagliptin and its active metabolite was less than 25%.</paragraph>
                        <paragraph>No appreciable accumulation of either saxagliptin or its active metabolite was observed with repeated once-daily dosing at any dose level. No dose- and time-dependence were observed in the clearance of saxagliptin and its active metabolite over 14 days of once-daily dosing with saxagliptin at doses ranging from 2.5 to 400 mg.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_4c9c14f5-ad46-4245-9654-932af40a5c87">
                           <id root="41b26dcb-4bff-4f7e-881b-1c00b17e06f9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Absorption</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>The median time to maximum concentration (T<sub>max</sub>) following the 5 mg once daily dose was 2 hours for saxagliptin and 4 hours for its active metabolite. </paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_f54196fb-7a8b-4e9b-834f-9797ccbcdaff">
                           <id root="a9c99052-7c4e-4560-89da-b58c9b9c008b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Effect of Food</content>
                           </title>
                           <text>
                              <paragraph>Administration with a high-fat meal resulted in an increase in T<sub>max</sub> of saxagliptin by approximately 20 minutes as compared to fasted conditions. There was a 27% increase in the AUC of saxagliptin when given with a meal as compared to fasted conditions. Saxagliptin tablets may be administered with or without food.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_7eb0c40c-8267-4865-9aa1-cb41fc37c0b5">
                           <id root="dfa0ea85-aa0d-4d8d-8eae-e71c90819518"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Distribution</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>The <content styleCode="italics">in vitro</content> protein binding of saxagliptin and its active metabolite in human serum is negligible. Therefore, changes in blood protein levels in various disease states (e.g., renal or hepatic impairment) are not expected to alter the disposition of saxagliptin.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_8b2ab5e2-ac2c-4ddf-8f4a-89e7612ac8f8">
                           <id root="fb96a6df-d564-4b4b-8b21-bb34554fe835"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Elimination</content>
                           </title>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_fa77cb17-22bc-4d27-948b-781690e020d2">
                                 <id root="b5eb0ada-6cc2-411b-9029-599313b79ed5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Metabolism </title>
                                 <text>
                                    <paragraph>The metabolism of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5). The major metabolite of saxagliptin is also a DPP-4 inhibitor, which is one-half as potent as saxagliptin. Therefore, strong CYP3A4/5 inhibitors and inducers will alter the pharmacokinetics of saxagliptin and its active metabolite [<content styleCode="italics">see <linkHtml href="#ID_99a9906d-2407-433c-a6a1-00c0c0984acf">Drug Interactions (7.1)</linkHtml>
                                       </content>].</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_e04bf448-7aa8-442f-9f14-3aff938adb5e">
                                 <id root="0f2ac7f4-1360-4321-8c16-444bf4ac4d53"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Excretion </title>
                                 <text>
                                    <paragraph>Saxagliptin is eliminated by both renal and hepatic pathways. Following a single 50 mg dose of <sup>14</sup>C-saxagliptin, 24%, 36%, and 75% of the dose was excreted in the urine as saxagliptin, its active metabolite, and total radioactivity, respectively. The average renal clearance of saxagliptin (~ 230 mL/min) was greater than the average estimated glomerular filtration rate (~ 120 mL/min), suggesting some active renal excretion. A total of 22% of the administered radioactivity was recovered in feces representing the fraction of the saxagliptin dose excreted in bile and/or unabsorbed drug from the gastrointestinal tract. Following a single oral dose of saxagliptin tablets 5 mg to healthy subjects, the mean plasma terminal half-life (t<sub>1/2</sub>) for saxagliptin and its active metabolite was 2.5 and 3.1 hours, respectively.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_a117fc8b-c668-4a58-bb4e-a03cf2fce1a7">
                           <id root="739f5b45-5a08-446f-a267-19717c12564d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Specific Populations</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_6beddf8e-76b4-4c6e-80a0-be3e0aa26dd0">
                                 <id root="a70ce08e-c2a4-463b-bfb2-9d03ee689548"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Geriatric Patients </title>
                                 <text>
                                    <paragraph>No dosage adjustment is recommended based on age alone. Elderly subjects (65-80 years) had 23% and 59% higher geometric mean C<sub>max</sub> and geometric mean AUC values, respectively, for saxagliptin than young subjects (18-40 years). Differences in active metabolite pharmacokinetics between elderly and young subjects generally reflected the differences observed in saxagliptin pharmacokinetics. The difference between the pharmacokinetics of saxagliptin and the active metabolite in young and elderly subjects is likely due to multiple factors including declining renal function and metabolic capacity with increasing age. Age was not identified as a significant covariate on the apparent clearance of saxagliptin and its active metabolite in the population pharmacokinetic analysis.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_18a569b1-ffaa-4504-b3cb-6880e435695b">
                                 <id root="596517e5-2824-47d5-934d-06e1898006dd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Male and Female Patients </title>
                                 <text>
                                    <paragraph>No dosage adjustment is recommended based on gender. There were no differences observed in saxagliptin pharmacokinetics between males and females. Compared to males, females had approximately 25% higher exposure values for the active metabolite than males, but this difference is unlikely to be of clinical relevance. Gender was not identified as a significant covariate on the apparent clearance of saxagliptin and its active metabolite in the population pharmacokinetic analysis.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_2d907b20-960b-4cd6-ade7-7b3aad110b18">
                                 <id root="5f67ca5f-a045-4829-89f9-396c7c220b06"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Racial or Ethnic Groups </title>
                                 <text>
                                    <paragraph>No dosage adjustment is recommended based on race. The population pharmacokinetic analysis compared the pharmacokinetics of saxagliptin and its active metabolite in 309 White subjects with 105 subjects of other races (consisting of six racial groups). No significant difference in the pharmacokinetics of saxagliptin and its active metabolite were detected between these two populations.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_85484b8b-7476-4476-9339-eca28aa6396f">
                                 <id root="bb5f34e2-bcb9-492a-92dd-161c9c9608cf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Patients with Renal Impairment </title>
                                 <text>
                                    <paragraph>A single-dose, open-label trial was conducted to evaluate the pharmacokinetics of saxagliptin (10 mg dose) in subjects with varying degrees of chronic renal impairment compared to subjects with normal renal function. The 10 mg dosage is not an approved dosage. The degree of renal impairment did not affect C<sub>max</sub> of saxagliptin or its metabolite. In subjects with moderate renal impairment with (eGFR 30 to less than 45 mL/min/1.73 m<sup>2</sup>), severe renal impairment (eGFR 15 to less than 30 mL/min/1.73 m<sup>2</sup>) and ESRD patient on hemodialysis, the AUC values of saxagliptin or its active metabolite were &gt; 2 fold higher than AUC values in subjects with normal renal function.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_13750c92-8237-4a85-90d1-35051b360532">
                                 <id root="37475cae-3ac3-4cf1-91ce-3da9a58e86be"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Patients with Hepatic Impairment </title>
                                 <text>
                                    <paragraph>In subjects with hepatic impairment (Child-Pugh classes A, B, and C), mean C<sub>max</sub> and AUC of saxagliptin were up to 8% and 77% higher, respectively, compared to healthy matched controls following administration of a single 10 mg dose of saxagliptin. The 10 mg dosage is not an approved dosage. The corresponding C<sub>max</sub> and AUC of the active metabolite were up to 59% and 33% lower, respectively, compared to healthy matched controls. These differences are not considered to be clinically meaningful. </paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_bdadd8de-b59a-48ad-98f5-7f5d8cf3fe3c">
                                 <id root="f7884f0d-4985-4d91-9c3d-c24c834fbfbc"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Body Mass Index </title>
                                 <text>
                                    <paragraph>No dosage adjustment is recommended based on body mass index (BMI) which was not identified as a significant covariate on the apparent clearance of saxagliptin or its active metabolite in the population pharmacokinetic analysis.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_9ea27229-c5c1-4d73-b39c-45948680a55b">
                           <id root="5ed3a5b2-d3f9-4d1f-8ffe-af89d87866a5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Drug Interaction Studies</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_50d76e8e-debf-4da9-87ee-330ec736b961">
                                 <id root="50d76e8e-debf-4da9-87ee-330ec736b961"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>In Vitro Assessment of Drug Interactions </title>
                                 <text>
                                    <paragraph>The metabolism of saxagliptin is primarily mediated by CYP3A4/5.</paragraph>
                                    <paragraph>In <content styleCode="italics">in vitro</content> studies, saxagliptin and its active metabolite did not inhibit CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, or 3A4, or induce CYP1A2, 2B6, 2C9, or 3A4. Therefore, saxagliptin is not expected to alter the metabolic clearance of coadministered drugs that are metabolized by these enzymes. Saxagliptin is a P-glycoprotein (P-gp) substrate but is not a significant inhibitor or inducer of P-gp.</paragraph>
                                 </text>
                                 <effectiveTime value="20230423"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_9e136bf9-5bb7-4eaf-af5f-c8c22659159d">
                                 <id root="1b878819-b100-4cd8-b66e-efc16a5a5184"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">In Vivo Assessment of Drug Interactions</content>
                                 </title>
                                 <text>
                                    <table width="100%">
                                       <caption>Table 2: Effect of Coadministered Drugs on Systemic Exposures of Saxagliptin and its Active Metabolite, 5-hydroxy Saxagliptin</caption>
                                       <col width="18%"/>
                                       <col width="22%"/>
                                       <col width="20%"/>
                                       <col width="21%"/>
                                       <col width="8%"/>
                                       <col width="10%"/>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="6" valign="top">ND = not determined; QD = once daily; q6h = every 6 hours; q12h = every 12 hours; BID = twice daily; LA = long acting.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Coadministered<br/>Drug</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Dosage of<br/>Coadministered Drug</content>
                                                   <footnote ID="_Ref527017369">Single dose unless otherwise noted. The 10 mg saxagliptin dose is not an approved dosage.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Dosage of<br/>Saxagliptin</content>
                                                   <footnoteRef IDREF="_Ref527017369"/>
                                                </paragraph>
                                             </td>
                                             <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Geometric Mean Ratio<br/>(ratio with/without coadministered drug)<br/>No Effect = 1.00</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">AUC</content>
                                                   <footnote ID="_Ref527017382">AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">C<sub>max</sub>
                                                   </content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">No dosing adjustments required for the following:</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Metformin</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1,000 mg</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>100 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.98</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.79</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.99</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.88</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Glyburide</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5 mg</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.98</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.08</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Dapagliflozin</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg single dose</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5 mg single dose</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>â 1%</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>â 7%</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>â 9%</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>â 6%</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Pioglitazone<footnote ID="_Ref527017404">Results exclude one subject.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>45 mg QD for 10 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg QD for 5 days</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.11</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.11</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Digoxin</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.25 mg q6h first day followed by q12h second day followed by QD for 5 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg QD for 7 days</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.05</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.99</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.06</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.02</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Simvastatin</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>40 mg QD for 8 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg QD for 4 days</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.12</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.21</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.02</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.08</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Diltiazem</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>360 mg LA QD for 9 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>2.09</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.63</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.66</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.57</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Rifampin<footnote ID="_Ref527017426">The plasma DPP-4 activity inhibition over a 24-hour dose interval was not affected by rifampin.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>600 mg QD for 6 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.24</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.47</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.03</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.39</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Omeprazole</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>40 mg QD for 5 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.13</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.98</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Aluminum hydroxide + magnesium hydroxide + simethicone</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>aluminum hydroxide: 2400 mg</paragraph>
                                                <paragraph>magnesium hydroxide: 2400 mg</paragraph>
                                                <paragraph>simethicone: 240 mg</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.97</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.74</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Famotidine</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>40 mg</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.03</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.14</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Limit saxagliptin tablet dose to 2.5 mg once daily when coadministered with strong CYP3A4/5 inhibitors [<content styleCode="italics">seeÂ <linkHtml href="#ID_99a9906d-2407-433c-a6a1-00c0c0984acf">Drug Interactions (7.1)</linkHtml> and <linkHtml href="#ID_4e83fe0a-9a92-4dde-be1b-daaf9217bddd">Dosage and Administration (2.3)</linkHtml>
                                                      </content>]:</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Ketoconazole</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>200 mg BID for 9 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>100 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>2.45</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.62</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.12</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.05</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Ketoconazole</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>200 mg BID for 7 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>20 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>3.67</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>2.44</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>5-hydroxy saxagliptin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Â </paragraph>
                                    <table width="100%">
                                       <caption>Table 3: Effect of Saxagliptin on Systemic Exposures of Coadministered Drugs</caption>
                                       <col width="18%"/>
                                       <col width="23%"/>
                                       <col width="21%"/>
                                       <col width="22%"/>
                                       <col width="8%"/>
                                       <col width="9%"/>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="6" valign="top">ND = not determined; QD = once daily; q6h = every 6 hours; q12h = every 12 hours; BID = twice daily; LA = long acting.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Coadministered<br/>Drug</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Dosage of<br/>Coadministered Drug</content>
                                                   <footnote ID="_Ref527017637">Single dose unless otherwise noted. The 10 mg and 100 mg saxagliptin doses are not approved dosages.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Dosage of<br/>Saxagliptin</content>
                                                   <footnoteRef IDREF="_Ref527017637"/>
                                                </paragraph>
                                             </td>
                                             <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Geometric Mean Ratio<br/>(ratio with/without saxagliptin)<br/>No Effect = 1.00</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">AUC</content>
                                                   <footnote ID="_Ref527017649">AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">C<sub>max</sub>
                                                   </content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="6" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">No dosing adjustments required for the following:</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Metformin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1,000 mg</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>100 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>metformin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.20</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.09</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Glyburide</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5 mg</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>glyburide</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.06</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.16</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Pioglitazone<footnote ID="_Ref527017670">Results include all subjects.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>45 mg QD for 10 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg QD for 5 days</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>pioglitazone</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.08</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.14</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>hydroxy-pioglitazone</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ND</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Digoxin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.25 mg q6h first day followed by q12h second day followed by QD for 5 days</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg QD for 7 days</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>digoxin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.06</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.09</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Simvastatin</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>40 mg QD for 8 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg QD for 4 days</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>simvastatin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.04</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.88</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>simvastatin acid</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.16</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.00</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Diltiazem</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>360 mg LA QD for 9 days</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>10 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>diltiazem</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.16</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Ketoconazole</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>200 mg BID for 9 days</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>100 mg</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ketoconazole</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.87</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.84</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td rowspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>Ethinyl estradiol and Norgestimate</paragraph>
                                             </td>
                                             <td align="center" rowspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ethinyl estradiol 0.035 mg and norgestimate 0.250 mg for 21 days</paragraph>
                                             </td>
                                             <td align="center" rowspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5 mg QD for 21 days</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>ethinyl estradiol</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.07</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.98</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>norelgestromin</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>1.09</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>norgestrel</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>1.13</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>1.17</paragraph>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_26b367e4-dd21-40ad-8565-08d804851fdc">
               <id root="60040e59-1842-48b5-98de-a6bfbdc6def7"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250228"/>
               <component>
                  <section ID="ID_caaab132-8cee-491b-9101-48fdc12cdb75">
                     <id root="45749c23-9bf3-41de-b2ce-3f4493ec7e15"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_d30252df-a1a7-4999-a07a-9947f0b3be8b">
                           <id root="4fe8e347-1a43-4c67-b710-dacc07c4e67a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Carcinogenesis</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Carcinogenicity was evaluated in 2-year studies conducted in CD-1 mice and Sprague-Dawley rats. Saxagliptin did not increase the incidence of tumors in mice dosed orally at 50, 250, and 600 mg/kg up to 870-times (males) and 1165-times (females) the 5 mg/day clinical dose, based on AUC. Saxagliptin did not increase the incidence of tumors in rats dosed orally at 25, 75, 150, and 300 mg/kg up to 355-times (males) and 2217-times (females) the 5 mg/day clinical dose, based on AUC.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_267aa78d-cd15-4608-8c61-ef6972e1ad95">
                           <id root="160c77b1-3491-42a1-9a29-d23fb60bf13d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Mutagenesis</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Saxagliptin was not mutagenic or clastogenic in a battery of genotoxicity tests (Ames bacterial mutagenesis, human and rat lymphocyte cytogenetics, rat bone marrow micronucleus and DNA repair assays). The active metabolite of saxagliptin was not mutagenic in an Ames bacterial assay.</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_db16f13e-fab7-4c37-817c-2a21185cd11f">
                           <id root="a4666c1f-f00f-45db-8ccb-e2a5f2a2f42c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Impairment of Fertility</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Saxagliptin administered to rats had no effect on fertility or the ability to maintain a litter at exposures up to 603-times and 776-times the 5 mg clinical dose in males and females, based on AUC. </paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_74b5d893-b070-4b74-8a71-eca1808beb4e">
                     <id root="74b5d893-b070-4b74-8a71-eca1808beb4e"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology </title>
                     <text>
                        <paragraph>Saxagliptin produced adverse skin changes in the extremities of cynomolgus monkeys (scabs and/or ulceration of tail, digits, scrotum, and/or nose). Skin lesions were reversible within exposure approximately 20-times the 5 mg clinical dose, but in some cases were irreversible and necrotizing at higher exposures. Adverse skin changes were not observed at exposures similar to (1- to 3-times) the 5 mg clinical dose. Clinical correlates to skin lesions in monkeys have not been observed in human clinical trials of saxagliptin.</paragraph>
                     </text>
                     <effectiveTime value="20230423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_43e63f5d-9fde-4c5d-8066-5331284d3c9c">
               <id root="340b6dc9-f404-440f-b00d-242f50a91e2e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20250228"/>
               <component>
                  <section ID="ID_4d143056-ea3c-4518-a9e6-575f0134feb9">
                     <id root="45a9ccb6-25eb-4234-a17d-70b706762f70"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Glycemic Control Trials in Adults with Type 2 Diabetes Mellitus </title>
                     <text>
                        <paragraph>Saxagliptin tablets have been studied as monotherapy and in combination with metformin HCl, glyburide, and thiazolidinedione (pioglitazone and rosiglitazone) therapy.</paragraph>
                        <paragraph>A total of 4148 patients with type 2 diabetes mellitus were randomized in six, double-blind, controlled clinical trials conducted to evaluate the safety and glycemic efficacy of saxagliptin tablets administered orally. A total of 3021 patients in these trials were treated with saxagliptin tablets. In these trials, the mean age was 54 years, and 71% of patients were White, 16% were Asian, 4% were Black or African American, and 9% were of other racial groups. An additional 423 patients, including 315 who received saxagliptin tablets, participated in a placebo-controlled, dose-ranging trial of 6 to 12 weeks in duration.</paragraph>
                        <paragraph>In these six, double-blind trials, saxagliptin tablets were evaluated at doses of 2.5 mg and 5 mg once daily. Three of these trials also evaluated a saxagliptin tablet dose of 10 mg daily. The 10 mg daily dose of saxagliptin tablets did not provide greater efficacy than the 5 mg daily dose. The 10 mg dosage is not an approved dosage. Treatment with saxagliptin tablets 5 mg and 2.5 mg doses produced statistically significant improvements in A1C, fasting plasma glucose (FPG), and 2-hour postprandial glucose (PPG) following a standard oral glucose tolerance test (OGTT), compared to control. Reductions in A1C were seen across subgroups including gender, age, race, and baseline BMI.</paragraph>
                        <paragraph>Saxagliptin tablets were not associated with significant changes from baseline in body weight or fasting serum lipids compared to placebo.</paragraph>
                        <paragraph>Saxagliptin tablets have also been evaluated in five additional trials in patients with type 2 diabetes mellitus: an active-controlled trial comparing add-on therapy with saxagliptin tablets to glipizide in 858 patients inadequately controlled on metformin HCl alone, a trial comparing saxagliptin tablets to placebo in 455 patients inadequately controlled on insulin alone or on insulin in combination with metformin HCl, a trial comparing saxagliptin tablets to placebo in 257 patients inadequately controlled on metformin HCl plus a sulfonylurea, a trial comparing saxagliptin tablets to placebo in 315 patients inadequately controlled on dapagliflozin and metformin HCl, and a trial comparing saxagliptin tablets to placebo in 170 patients with type 2 diabetes mellitus and moderate or severe renal impairment or ESRD.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="ID_c59773d6-36cd-4ada-8bbd-c9a1e5499436">
                           <id root="9a3cebc3-51ff-4876-8428-3f5ffba6a6a2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Monotherapy</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>A total of 766 patients with type 2 diabetes mellitus inadequately controlled on diet and exercise (A1C â¥ 7% to â¤ 10%) participated in two 24-week, double-blind, placebo-controlled trials evaluating the efficacy and safety of saxagliptin tablet monotherapy.</paragraph>
                              <paragraph>In the first trial, following a 2-week single-blind diet, exercise, and placebo lead-in period, 401 patients were randomized to 2.5 mg, 5 mg, or 10 mg of saxagliptin tablets or placebo. The 10 mg dosage is not an approved dosage. Patients who failed to meet specific glycemic goals during the trial were treated with metformin HCl rescue therapy, added on to placebo or saxagliptin tablets. Efficacy was evaluated at the last measurement prior to rescue therapy for patients needing rescue. Dose titration of saxagliptin tablets was not permitted.</paragraph>
                              <paragraph>Treatment with saxagliptin tablets 2.5 mg and 5 mg daily provided significant improvements in A1C, FPG, and PPG compared to placebo (Table 4). The percentage of patients who discontinued for lack of glycemic control or who were rescued for meeting prespecified glycemic criteria was 16% in the saxagliptin tablets 2.5 mg treatment group, 20% in the saxagliptin tablets 5 mg treatment group, and 26% in the placebo group.</paragraph>
                              <table width="100%">
                                 <caption>Table 4: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin Tablet Monotherapy in Patients with Type 2 Diabetes Mellitus<footnote ID="_Ref527017855">Intent-to-treat population using last observation on trial or last observation prior to metformin HCl rescue therapy for patients needing rescue</footnote>
                                 </caption>
                                 <col width="48%"/>
                                 <col width="17%"/>
                                 <col width="19%"/>
                                 <col width="16%"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Efficacy Parameter</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Saxagliptin</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">Tablets</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">2.5 mg</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">N = 102</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Saxagliptin</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">Tablets</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">5 mg</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">N = 106</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Placebo</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">Â </content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">Â </content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">N = 95</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Hemoglobin A1C (%)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">N = 100</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">N = 103</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">N = 92</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Baseline (mean)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>7.9</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>8.0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>7.9</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Change from baseline (adjusted mean<footnote ID="_Ref527017877">Least squares mean adjusted for baseline value.</footnote>)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-0.4</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-0.5</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>+0.2</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527017877"/>)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-0.6<footnote ID="_Ref527017905">p-value &lt; 0.0001 compared to placebo.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-0.6<footnoteRef IDREF="_Ref527017905"/>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>(-0.9, -0.3)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>(-0.9, -0.4)</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Percent of patients achieving A1C &lt; 7%</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>35% (35/100)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>38%<footnote ID="_Ref527017925">p-value &lt; 0.05 compared to placebo.</footnote> (39/103)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>24% (22/92)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">N = 101</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">N = 105</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">N = 92</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Baseline (mean)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>178</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>171</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>172</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527017877"/>)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-15</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-9</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>+6</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527017877"/>)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-21<footnoteRef IDREF="_Ref527017925"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-15<footnoteRef IDREF="_Ref527017925"/>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>(-31, -10)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>(-25, -4)</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">2-hour Postprandial Glucose (mg/dL)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">N = 78</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">N = 84</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">N = 71</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Baseline (mean)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>279</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>278</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>283</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527017877"/>)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-45</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-43</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-6</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527017877"/>)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-39<footnote ID="_Ref527017960">Significance was not tested for the 2-hour PPG for the 2.5 mg dose of saxagliptin tablets.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>-37<footnoteRef IDREF="_Ref527017925"/>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>(-61, -16)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>(-59, -15)</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>A second 24-week monotherapy trial was conducted to assess a range of dosing regimens for saxagliptin tablets. Treatment-naive patients with inadequately controlled type 2 diabetes mellitus (A1C â¥ 7% to â¤ 10%) underwent a 2-week, single-blind diet, exercise, and placebo lead-in period. A total of 365 patients were randomized to 2.5 mg every morning, 5 mg every morning, 2.5 mg with possible titration to 5 mg every morning, or 5 mg every evening of saxagliptin tablets, or placebo. Patients who failed to meet specific glycemic goals during the trial were treated with metformin HCl rescue therapy added on to placebo or saxagliptin tablets; the number of patients randomized per treatment group ranged from 71 to 74.</paragraph>
                              <paragraph>Treatment with either saxagliptin tablets 5 mg every morning or 5 mg every evening provided significant improvements in A1C versus placebo (mean placebo-corrected reductions of -0.4% and -0.3%, respectively). Treatment with saxagliptin tablets 2.5 mg every morning also provided significant improvement in A1C versus placebo (mean placebo-corrected reduction of -0.4%).</paragraph>
                           </text>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_8baeeaec-29ae-46d7-b7a6-4b88cc9a709b">
                           <id root="cffb9a87-2b1a-40a7-82c9-504451b7bed8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Combination Therapy</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <effectiveTime value="20250228"/>
                           <component>
                              <section ID="ID_005f3fd9-fdc8-4c32-afb5-2257fa2bf13a">
                                 <id root="17aace31-2909-49bf-aadf-27711b160a1a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Add-On Combination Therapy with Metformin HCl </title>
                                 <text>
                                    <paragraph>A total of 743 patients with type 2 diabetes mellitus participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of saxagliptin tablets in combination with metformin HCl in patients with inadequate glycemic control (A1C â¥ 7% and â¤ 10%) on metformin HCl alone. To qualify for enrollment, patients were required to be on a stable dose of metformin HCl (1,500-2,550 mg daily) for at least 8 weeks.</paragraph>
                                    <paragraph>Patients who met eligibility criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo lead-in period during which patients received metformin HCl at their pre-trial dose, up to 2,500 mg daily. Following the lead-in period, eligible patients were randomized to 2.5 mg, 5 mg, or 10 mg of saxagliptin tablets or placebo in addition to their current dose of open-label metformin HCl. The 10 mg dosage of saxagliptin tablets is not an approved dosage. Patients who failed to meet specific glycemic goals during the trial were treated with pioglitazone rescue therapy, added on to existing trial medications. Dose titrations of saxagliptin tablets and metformin HCl were not permitted.</paragraph>
                                    <paragraph>Saxagliptin tablets 2.5 mg and 5 mg add-on to metformin HCl provided significant improvements in A1C, FPG, and PPG compared with placebo add-on to metformin HCl (Table 5). Mean changes from baseline for A1C over time and at endpoint are shown in Figure 1. The proportion of patients who discontinued for lack of glycemic control or who were rescued for meeting prespecified glycemic criteria was 15% in the saxagliptin tablets 2.5 mg add-on to metformin HCl group, 13% in the saxagliptin tablets 5 mg add-on to metformin HCl group, and 27% in the placebo add-on to metformin HCl group.</paragraph>
                                    <table width="100%">
                                       <caption>Table 5: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin Tablets as Add-On Combination Therapy with Metformin HCl<footnote ID="_Ref527018137">Intent-to-treat population using last observation on trial or last observation prior to pioglitazone rescue therapy for patients needing rescue.</footnote>
                                       </caption>
                                       <col width="48%"/>
                                       <col width="17%"/>
                                       <col width="18%"/>
                                       <col width="17%"/>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Efficacy Parameter</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin<br/>Tablets 2.5 mg <br/>+ <br/>Metformin HCl<br/>N = 192</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin<br/>Tablets 5 mg <br/>+ <br/>Metformin HCl<br/>N = 191</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Placebo <br/>+ <br/>Metformin <br/>HCl<br/>N = 179</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Hemoglobin A1C (%)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 186</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 186</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 175</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.1</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnote ID="_Ref527018150">Least squares mean adjusted for baseline value.</footnote>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.6</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.7</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>+0.1</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<sup>â </sup>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.7<footnote ID="_Ref527018160">p-value &lt; 0.0001 compared to placebo + metformin HCl.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.8<footnoteRef IDREF="_Ref527018160"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.9, -0.5)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-1.0, -0.6)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Percent of patients achieving A1C &lt; 7%</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>37%<footnote ID="_Ref527018181">p-value &lt; 0.05 compared to placebo + metformin HCl.</footnote> (69/186)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>44%<footnoteRef IDREF="_Ref527018181"/> (81/186)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>17% (29/175)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 188</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 187</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 176</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>174</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>179</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>175</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527018150"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-14</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-22</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>+1</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527018150"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-16<footnoteRef IDREF="_Ref527018181"/>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-23<footnoteRef IDREF="_Ref527018181"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-23, -9)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-30, -16)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">2-hour Postprandial Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 155</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 155</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 135</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>294</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>296</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>295</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527018150"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-62</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-58</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-18</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527018150"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-44<footnoteRef IDREF="_Ref527018181"/>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-40<footnoteRef IDREF="_Ref527018181"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-60, -27)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-56, -24)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Â </paragraph>
                                    <renderMultiMedia ID="id-1642272077" referencedObject="f4b022ae-6891-4f36-8658-25364f3c293c">
                                       <caption>Figure 1: Mean Change from Baseline in A1C in a Placebo-Controlled Trial of Saxagliptin Tablets as Add-On Combination Therapy with Metformin HCl<sup>*</sup>
                                       </caption>
                                    </renderMultiMedia>
                                    <paragraph>Week 24 (LOCF) includes intent-to-treat population using last observation on trial prior to pioglitazone rescue therapy for patients needing rescue. Mean change from baseline is adjusted for baseline value.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                                 <component>
                                    <observationMedia ID="f4b022ae-6891-4f36-8658-25364f3c293c">
                                       <text>Figure 1: Mean Change from Baseline in A1C in a Placebo-Controlled Trial of Saxagliptin Tablets as Add-On Combination Therapy with Metformin HCl</text>
                                       <value mediaType="image/jpeg" xsi:type="ED">
                                          <reference value="image-02.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_895ffcc8-db9c-4ae6-b8e2-11e26c51c559">
                                 <id root="f4089fdd-735e-497f-8a7e-cb401e081b3e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Add-On Combination Therapy with a Thiazolidinedione </title>
                                 <text>
                                    <paragraph>A total of 565 patients with type 2 diabetes mellitus participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of saxagliptin tablets in combination with a thiazolidinedione (TZD) in patients with inadequate glycemic control (A1C â¥ 7% to â¤ 10.5%) on TZD alone. To qualify for enrollment, patients were required to be on a stable dose of pioglitazone (30-45 mg once daily) or rosiglitazone (4 mg once daily or 8 mg either once daily or in two divided doses of 4 mg) for at least 12 weeks.</paragraph>
                                    <paragraph>Patients who met eligibility criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo lead-in period during which patients received TZD at their pre-trial dose. Following the lead-in period, eligible patients were randomized to 2.5 mg or 5 mg of saxagliptin tablets or placebo in addition to their current dose of TZD. Patients who failed to meet specific glycemic goals during the trial were treated with metformin HCl rescue, added on to existing trial medications. Dose titration of saxagliptin tablets or TZD was not permitted during the trial. A change in TZD regimen from rosiglitazone to pioglitazone at specified, equivalent therapeutic doses was permitted at the investigatorâs discretion if believed to be medically appropriate.</paragraph>
                                    <paragraph>Saxagliptin tablets 2.5 mg and 5 mg add-on to TZD provided significant improvements in A1C, FPG, and PPG compared with placebo add-on to TZD (Table 6). The proportion of patients who discontinued for lack of glycemic control or who were rescued for meeting prespecified glycemic criteria was 10% in the saxagliptin tablets 2.5 mg add-on to TZD group, 6% for the saxagliptin tablets 5 mg add-on to TZD group, and 10% in the placebo add-on to TZD group.</paragraph>
                                    <table width="100%">
                                       <caption>Table 6: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin Tablets as Add-On Combination Therapy with a Thiazolidinedione<footnote ID="_Ref527018530">Intent-to-treat population using last observation on trial or last observation prior to metformin HCl rescue therapy for patients needing rescue.</footnote>
                                       </caption>
                                       <col width="48%"/>
                                       <col width="17%"/>
                                       <col width="19%"/>
                                       <col width="16%"/>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Efficacy Parameter</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin Tablets</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">2.5 mg + TZD</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">N = 195</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin Tablets</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">5 mg + TZD</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">N = 186</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Placebo + TZD</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">N = 184</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Hemoglobin A1C (%)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 192</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 183</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 180</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.3</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.4</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.2</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnote ID="_Ref527018550">Least squares mean adjusted for baseline value.</footnote>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.7</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.9</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.3</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527018550"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.4<footnote ID="_Ref527018601">p-value &lt; 0.05 compared to placebo + TZD.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.6<footnote ID="_Ref527018615">p-value &lt; 0.0001 compared to placebo + TZD.</footnote>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.6, -0.2)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.8, -0.4)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Percent of patients achieving A1C &lt; 7%</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>42%<footnoteRef IDREF="_Ref527018601"/> (81/192)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>42%<footnoteRef IDREF="_Ref527018601"/> (77/184)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>26% (46/180)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 193</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 185</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 181</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>163</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>160</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>162</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527018550"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-14</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-17</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-3</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527018550"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-12<footnoteRef IDREF="_Ref527018601"/>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-15<footnoteRef IDREF="_Ref527018601"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-20, -3)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-23, -6)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">2-hour Postprandial Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 156</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 134</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 127</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>296</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>303</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>291</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527018550"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-55</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-65</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-15</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527018550"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-40<footnoteRef IDREF="_Ref527018601"/>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-50<footnoteRef IDREF="_Ref527018601"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-56, -24)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-66, -34)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_878ee1f7-edd9-42bc-8566-e78872f9c7d2">
                                 <id root="05874a79-65a9-4630-b9f8-2e91d53398d9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Add-On Combination Therapy with Glyburide </title>
                                 <text>
                                    <paragraph>A total of 768 patients with type 2 diabetes mellitus participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of saxagliptin tablets in combination with a sulfonylurea (SU) in patients with inadequate glycemic control at enrollment (A1C â¥ 7.5% to â¤ 10%) on a submaximal dose of SU alone. To qualify for enrollment, patients were required to be on a submaximal dose of SU for 2 months or greater. In this trial, saxagliptin tablets in combination with a fixed, intermediate dose of SU was compared to titration to a higher dose of SU.</paragraph>
                                    <paragraph>Patients who met eligibility criteria were enrolled in a single-blind, 4-week, dietary and exercise lead-in period, and placed on glyburide 7.5 mg once daily. Following the lead-in period, eligible patients with A1C â¥ 7% to â¤ 10% were randomized to either 2.5 mg or 5 mg of saxagliptin tablets add-on to 7.5 mg glyburide or to placebo plus a 10 mg total daily dose of glyburide. Patients who received placebo were eligible to have glyburide up-titrated to a total daily dose of 15 mg. Up-titration of glyburide was not permitted in patients who received saxagliptin tablets 2.5 mg or 5 mg. Glyburide could be down-titrated in any treatment group once during the 24-week trial period due to hypoglycemia as deemed necessary by the investigator. Approximately 92% of patients in the placebo plus glyburide group were up-titrated to a final total daily dose of 15 mg during the first 4 weeks of the trial period. Patients who failed to meet specific glycemic goals during the trial were treated with metformin HCl rescue, added on to existing trial medication. Dose titration of saxagliptin tablets was not permitted during the trial.</paragraph>
                                    <paragraph>In combination with glyburide, saxagliptin tablets 2.5 mg and 5 mg provided significant improvements in A1C, FPG, and PPG compared with the placebo plus up-titrated glyburide group (Table 7). The proportion of patients who discontinued for lack of glycemic control or who were rescued for meeting prespecified glycemic criteria was 18% in the saxagliptin tablets 2.5 mg add-on to glyburide group, 17% in the saxagliptin tablets 5 mg add-on to glyburide group, and 30% in the placebo plus up-titrated glyburide group.</paragraph>
                                    <table width="100%">
                                       <caption>Table 7: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin Tablets as Add-On Combination Therapy with Glyburide<footnote ID="_Ref527019715">Intent-to-treat population using last observation on trial or last observation prior to metformin HCl rescue therapy for patients needing rescue.</footnote>
                                       </caption>
                                       <col width="48%"/>
                                       <col width="17%"/>
                                       <col width="19%"/>
                                       <col width="16%"/>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Efficacy Parameter</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin<br/>Tablets 2.5 mg <br/>+ <br/>Glyburide </content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">7.5 mg<br/>N = 248</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin  </content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">Tablets 5 mg <br/>+ <br/>Glyburide<br/>7.5 mg<br/>N = 253</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Placebo <br/>+ <br/>Up-Titrated<br/>Glyburide<br/>N = 267</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Hemoglobin A1C (%)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 246</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 250</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 264</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.4</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.4</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnote ID="_Ref527019727">Least squares mean adjusted for baseline value.</footnote>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.6</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>+0.1</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from up-titrated glyburide (adjusted mean<footnoteRef IDREF="_Ref527019727"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.6<footnote ID="_Ref527019790">p-value &lt; 0.0001 compared to placebo + up-titrated glyburide.</footnote>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.7<footnoteRef IDREF="_Ref527019790"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.8, -0.5)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.9, -0.6)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Percent of patients achieving A1C &lt; 7%</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>22%<footnote ID="_Ref527019807">p-value &lt; 0.05 compared to placebo + up-titrated glyburide.</footnote> (55/246)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>23%<footnoteRef IDREF="_Ref527019807"/> (57/250)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>9% (24/264)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 247</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 252</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 265</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>170</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>175</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>174</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527019727"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-7</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>+1</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from up-titrated glyburide (adjusted mean<footnoteRef IDREF="_Ref527019727"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-8<footnoteRef IDREF="_Ref527019807"/>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-10<footnoteRef IDREF="_Ref527019807"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-14, -1)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-17, -4)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">2-hour Postprandial Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 195</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 202</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 206</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>309</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>315</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>323</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527019727"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-31</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-34</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>+8</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from up-titrated glyburide (adjusted mean<footnoteRef IDREF="_Ref527019727"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-38<footnoteRef IDREF="_Ref527019807"/>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-42<footnoteRef IDREF="_Ref527019807"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-50, -27)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-53, -31)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_50ea90ba-210d-4e65-a4b7-0aa1a8215fff">
                                 <id root="400c636a-af40-4ac8-859d-1517b8988c21"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Coadministration with Metformin HCl in Treatment-Naive Patients </title>
                                 <text>
                                    <paragraph>A total of 1306 treatment-naive patients with type 2 diabetes mellitus participated in this 24-week, randomized, double-blind, active-controlled trial to evaluate the efficacy and safety of saxagliptin tablets coadministered with metformin HCl in patients with inadequate glycemic control (A1C â¥ 8% to â¤ 12%) on diet and exercise alone. Patients were required to be treatment-naive to be enrolled in this trial.</paragraph>
                                    <paragraph>Patients who met eligibility criteria were enrolled in a single-blind, 1-week, dietary and exercise placebo lead-in period. Patients were randomized to one of four treatment arms: saxagliptin tablets 5 mg + metformin HCl 500 mg, saxagliptin 10 mg + metformin HCl 500 mg, saxagliptin 10 mg + placebo, or metformin HCl 500 mg + placebo. The 10 mg saxagliptin dosage is not an approved dosage. Saxagliptin tablets were dosed once daily. In the 3 treatment groups using metformin HCl, the metformin HCl dose was up-titrated weekly in 500 mg per day increments, as tolerated, to a maximum of 2,000 mg per day based on FPG. Patients who failed to meet specific glycemic goals during the trials were treated with pioglitazone rescue as add-on therapy.</paragraph>
                                    <paragraph>Coadministration of saxagliptin tablets 5 mg plus metformin HCl provided significant improvements in A1C, FPG, and PPG compared with placebo plus metformin HCl (Table 8).</paragraph>
                                    <table width="100%">
                                       <caption>Table 8: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin Tablet Coadministration with Metformin HCl in Treatment-Naive Patients<footnote ID="_Ref527019987">Intent-to-treat population using last observation on trial or last observation prior to pioglitazone rescue therapy for patients needing rescue.</footnote>
                                       </caption>
                                       <col width="54%"/>
                                       <col width="23%"/>
                                       <col width="22%"/>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Efficacy Parameter</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin Tablets 5 mg <br/>+ <br/>Metformin HCl<br/>N = 320</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Placebo <br/>+ <br/>Metformin HCl<br/>N = 328</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Hemoglobin A1C (%)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 306</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 313</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>9.4</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>9.4</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnote ID="_Ref527019993">Least squares mean adjusted for baseline value.</footnote>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-2.5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-2.0</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo + metformin HCl (adjusted mean<footnoteRef IDREF="_Ref527019993"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.5<footnote ID="_Ref527020052">p-value &lt; 0.0001 compared to placebo + metformin.</footnote>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.7, -0.4)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Percent of patients achieving A1C &lt; 7%</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>60%<footnote ID="_Ref527020061">p-value &lt; 0.05 compared to placebo + metformin.</footnote> (185/307)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>41% (129/314)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 315</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 320</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>199</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>199</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527019993"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-60</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-47</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo + metformin HCl (adjusted mean<footnoteRef IDREF="_Ref527019993"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-13<footnoteRef IDREF="_Ref527020061"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-19, -6)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">2-hour Postprandial Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 146</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 141</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>340</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>355</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527019993"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-138</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-97</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo + metformin HCl (adjusted mean<footnoteRef IDREF="_Ref527019993"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-41<footnoteRef IDREF="_Ref527020061"/>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-57, -25)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_131ed687-711e-4829-91ae-cda3f0a4f0a1">
                                 <id root="5b285899-22a7-4bf0-a7af-a105c45df00a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Add-On Combination Therapy with Metformin HCl versus Glipizide Add-On Combination Therapy with Metformin HCl </title>
                                 <text>
                                    <paragraph>In this 52-week, active-controlled trial, a total of 858 patients with type 2 diabetes mellitus and inadequate glycemic control (A1C &gt; 6.5% and â¤ 10%) on metformin HCl alone were randomized to double-blind add-on therapy with saxagliptin tablets or glipizide. Patients were required to be on a stable dose of metformin HCl (at least 1,500 mg daily) for at least 8 weeks prior to enrollment.</paragraph>
                                    <paragraph>Patients who met eligibility criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo lead-in period during which patients received metformin HCl (1,500-3,000 mg based on their pre-trial dose). Following the lead-in period, eligible patients were randomized to 5 mg of saxagliptin tablets or 5 mg of glipizide in addition to their current dose of open-label metformin HCl. Patients in the glipizide plus metformin HCl group underwent blinded titration of the glipizide dose during the first 18 weeks of the trial up to a maximum glipizide dose of 20 mg per day. Titration was based on a goal FPG â¤ 110 mg/dL or the highest tolerable glipizide dose. Fifty percent (50%) of the glipizide-treated patients were titrated to the 20-mg daily dose; 21% of the glipizide-treated patients had a final daily glipizide dose of 5 mg or less. The mean final daily dose of glipizide was 15 mg.</paragraph>
                                    <paragraph>After 52 weeks of treatment, saxagliptin tablets and glipizide resulted in similar mean reductions from baseline in A1C when added to metformin HCl therapy (Table 9). This conclusion may be limited to patients with baseline A1C comparable to those in the trial (91% of patients had baseline A1C &lt; 9%).</paragraph>
                                    <paragraph>From a baseline mean body weight of 89 kg, there was a statistically significant mean reduction of 1.1 kg in patients treated with saxagliptin tablets compared to a mean weight gain of 1.1 kg in patients treated with glipizide (p &lt; 0.0001).</paragraph>
                                    <table width="100%">
                                       <caption>Table 9: Glycemic Parameters at Week 52 in an Active-Controlled Trial of Saxagliptin Tablets versus Glipizide in Combination with Metformin HCl<footnote ID="_Ref527020806">Intent-to-treat population using last observation on trial.</footnote>
                                       </caption>
                                       <col width="54%"/>
                                       <col width="23%"/>
                                       <col width="22%"/>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Efficacy Parameter</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin Tablets 5 mg <br/>+ <br/>Metformin HCl<br/>N = 428</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Titrated Glipizide <br/>+ <br/>Metformin HCl<br/>N = 430</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Hemoglobin A1C (%)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 423</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 423</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>7.7</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>7.6</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnote ID="_Ref527020816">Least squares mean adjusted for baseline value.</footnote>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.6</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.7</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from glipizide + metformin HCl (adjusted mean<footnoteRef IDREF="_Ref527020816"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>0.1</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.02, 0.2)<footnote ID="_Ref527020909">Saxagliptin tablets + metformin HCl is considered non-inferior to glipizide + metformin HCl because the upper limit of this confidence interval is less than the prespecified non-inferiority margin of 0.35%.</footnote>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 420</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 420</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>162</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>161</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527020816"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-9</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-16</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from glipizide + metformin HCl (adjusted mean<footnoteRef IDREF="_Ref527020816"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>6</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(2, 11)<footnote ID="_Ref527020916">Significance not tested.</footnote>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Â </paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_33d09480-85c0-4db4-949c-0549dc8b29d1">
                                 <id root="4cffc54d-e7c4-4be7-9112-7ed919587b1a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Add-On Combination Therapy with Insulin (with or without metformin HCl) </title>
                                 <text>
                                    <paragraph>A total of 455 patients with type 2 diabetes mellitus participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of saxagliptin tablets in combination with insulin in patients with inadequate glycemic control (A1C â¥ 7.5% and â¤ 11%) on insulin alone (N = 141) or on insulin in combination with a stable dose of metformin HCl (N = 314). Patients were required to be on a stable dose of insulin (â¥ 30 units to â¤ 150 units daily) with â¤ 20% variation in total daily dose for â¥ 8 weeks prior to screening. Patients entered the trial on intermediate- or long-acting (basal) insulin or premixed insulin. Patients using short-acting insulins were excluded unless the short-acting insulin was administered as part of a premixed insulin.</paragraph>
                                    <paragraph>Patients who met eligibility criteria were enrolled in a single-blind, four-week, dietary and exercise placebo lead-in period during which patients received insulin (and metformin HCl if applicable) at their pretrial dose(s). Following the lead-in period, eligible patients were randomized to add-on therapy with either saxagliptin tablets 5 mg or placebo. Doses of the antidiabetic therapies were to remain stable but patients were rescued and allowed to adjust the insulin regimen if specific glycemic goals were not met or if the investigator learned that the patient had self-increased the insulin dose by &gt; 20%. Data after rescue were excluded from the primary efficacy analyses.</paragraph>
                                    <paragraph>Add-on therapy with saxagliptin tablets 5 mg provided significant improvements from baseline to Week 24 in A1C and PPG compared with add-on placebo (Table 10). Similar mean reductions in A1C versus placebo were observed for patients using saxagliptin tablets 5 mg add-on to insulin alone and saxagliptin tablets 5 mg add-on to insulin in combination with metformin HCl (-0.4% and -0.4%, respectively). The percentage of patients who discontinued for lack of glycemic control or who were rescued was 23% in the saxagliptin tablets group and 32% in the placebo group.</paragraph>
                                    <paragraph>The mean daily insulin dose at baseline was 53 units in patients treated with saxagliptin tablets 5 mg and 55 units in patients treated with placebo. The mean change from baseline in daily dose of insulin was 2 units for the saxagliptin tablets 5 mg group and 5 units for the placebo group.</paragraph>
                                    <table width="100%">
                                       <caption>Table 10: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin Tablets as Add-On Combination Therapy with Insulin<footnote ID="_Ref527021378">Intent-to-treat population using last observation on trial or last observation prior to insulin rescue therapy for patients needing rescue.</footnote>
                                       </caption>
                                       <col width="54%"/>
                                       <col width="23%"/>
                                       <col width="22%"/>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Efficacy Parameter</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin Tablets</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">5 mg + Insulin</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">(+/- Metformin HCl)</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">N = 304</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Placebo + Insulin</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">(+/- Metformin HCl)</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">N = 151</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Hemoglobin A1C (%)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 300</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 149</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.7</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.7</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnote ID="_Ref527021385">Least squares mean adjusted for baseline value and metformin HCl use at baseline.</footnote>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.7</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.3</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527021385"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.4<footnote ID="_Ref527021415">p-value &lt; 0.0001 compared to placebo + insulin.</footnote>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.6, -0.2)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">2-hour Postprandial Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 262</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 129</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>251</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>255</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527021385"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-27</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-4</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527021385"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-23<footnote ID="_Ref527021423">p-value &lt; 0.05 compared to placebo + insulin.</footnote>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-37, -9)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>The change in fasting plasma glucose from baseline to Week 24 was also tested, but was not statistically significant. The percent of patients achieving an A1C &lt; 7% was 17% (52/300) with saxagliptin tablets in combination with insulin compared to 7% (10/149) with placebo. Significance was not tested.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_09f88e4d-c9c8-4985-a52a-c9c3d2d0a4c5">
                                 <id root="c36398fb-853c-48af-a6c7-84e71618409d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Add-On Combination Therapy with Metformin HCl plus Sulfonylurea </title>
                                 <text>
                                    <paragraph>A total of 257 patients with type 2 diabetes mellitus participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of saxagliptin tablets in combination with metformin HCl plus a sulfonylurea in patients with inadequate glycemic control (A1C â¥ 7% and â¤ 10%). Patients were to be on a stable combined dose of metformin HCl extended-release or immediate-release (at maximum tolerated dose, with minimum dose for enrollment being 1,500 mg) and a sulfonylurea (at maximum tolerated dose, with minimum dose for enrollment being â¥ 50% of the maximum recommended dose) for â¥ 8 weeks prior to enrollment.</paragraph>
                                    <paragraph>Patients who met eligibility criteria were entered in a 2-week enrollment period to allow assessment of inclusion/exclusion criteria. Following the 2-week enrollment period, eligible patients were randomized to either double-blind saxagliptin tablets (5 mg once daily) or double-blind matching placebo for 24 weeks. During the 24-week double-blind treatment period, patients were to receive metformin HCl and a sulfonylurea at the same constant dose ascertained during enrollment. Sulfonylurea dose could be down titrated once in the case of a major hypoglycemic event or recurring minor hypoglycemic events. In the absence of hypoglycemia, titration (up or down) of trial medication during the treatment period was prohibited.</paragraph>
                                    <paragraph>Saxagliptin tablets in combination with metformin HCl plus a sulfonylurea provided significant improvements in A1C and PPG compared with placebo in combination with metformin HCl plus a sulfonylurea (Table 11). The percentage of patients who discontinued for lack of glycemic control was 6% in the saxagliptin tablets group and 5% in the placebo group.</paragraph>
                                    <table width="100%">
                                       <caption>Table 11: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of Saxagliptin Tablets as Add-On Combination Therapy with Metformin HCl plus Sulfonylurea<footnote ID="_Ref527021541">Intent-to-treat population using last observation prior to discontinuation.</footnote>
                                       </caption>
                                       <col width="53%"/>
                                       <col width="24%"/>
                                       <col width="22%"/>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Efficacy Parameter</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin Tablets 5 mg<br/>+ <br/>Metformin HCl plus<br/>Sulfonylurea<br/>N = 129</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Placebo <br/>+ <br/>Metformin HCl plus<br/>Sulfonylurea<br/>N = 128</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Hemoglobin A1C (%)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 127</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N =127</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.4</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.2</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnote ID="_Ref527021548">Least squares mean adjusted for baseline value.</footnote>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.7</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.1</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527021548"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.7<footnote ID="_Ref527021581">p-value &lt; 0.0001 compared to placebo + metformin HCl plus sulfonylurea.</footnote>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.9, -0.5)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">2-hour Postprandial Glucose (mg/dL)</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 115</content>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">N = 113</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>268</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>262</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Change from baseline (adjusted mean<footnoteRef IDREF="_Ref527021548"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-12</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>5</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527021548"/>)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-17<footnote ID="_Ref527021589">p-value &lt; 0.05 compared to placebo + metformin HCl plus sulfonylurea.</footnote>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-32, -2)</paragraph>
                                             </td>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>The change in fasting plasma glucose from baseline to Week 24 was also tested, but was not statistically significant. The percent of patients achieving an A1C &lt; 7% was 31% (39/127) with saxagliptin tablets in combination with metformin HCl plus a sulfonylurea compared to 9% (12/127) with placebo. Significance was not tested.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_fe5aada8-6281-416b-9051-8838edb85df9">
                                 <id root="80bb5b37-a39b-4fca-8fa5-afa5be1c3258"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Add-on Combination Therapy with Metformin HCl plus an SGLT2 Inhibitor </title>
                                 <text>
                                    <paragraph>A total of 315 patients with type 2 diabetes mellitus participated in this 24-week randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of saxagliptin tablets added to dapagliflozin (an SGLT2 inhibitor) and metformin HCl in patients with a baseline of HbA1c â¥ 7% to â¤ 10.5%. The mean age of these patients was 54.6 years, 1.6% were 75 years or older and 52.7% were female. The population was 87.9% White, 6.3% Black or African American, 4.1% Asian, and 1.6% other races. At baseline the population had diabetes mellitus for an average of 7.7 years and a mean HbA1c of 7.9%. The mean eGFR at baseline was 93.4 mL/min/1.73 m<sup>2</sup>. Patients were required to be on a stable dose of metformin HCl (â¥ 1,500 mg per day) for at least 8 weeks prior to enrollment. Eligible patients who completed the screening period entered the lead in treatment period, which included open-label metformin HCl and 10 mg dapagliflozin treatment. Following the lead-in period, eligible patients were randomized to saxagliptin tablets 5 mg (N = 153) or placebo (N = 162).</paragraph>
                                    <paragraph>The group treated with add-on saxagliptin tablets had statistically significant greater reductions in HbA1c from baseline versus the group treated with placebo (see Table 12).</paragraph>
                                    <table width="100%">
                                       <caption>Table 12:Â HbA1c Change from Baseline at Week 24 in a Placebo-Controlled Trial of Saxagliptin Tablets as Add-on to Dapagliflozin and Metformin HCl<footnote ID="_Ref191881930">There were 6.5% (n = 10) of randomized patients in the saxagliptin arm and 3.1% (n = 5) in the placebo arm for whom change from baseline HbA1c data was missing at week 24. Of the patients who discontinued trial medication early, 9.1% (1 of 11) in the saxagliptin arm and 16.7% (1 of 6) in the placebo arm had HbA1c measured at week 24.</footnote>
                                       </caption>
                                       <col width="45%"/>
                                       <col width="33%"/>
                                       <col width="22%"/>
                                       <tbody>
                                          <tr>
                                             <td rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Saxagliptin Tablets 5 mg</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">(N = 153)</content>
                                                   <footnote ID="_Ref191881953">Number of randomized and treated patients.</footnote>
                                                   <content styleCode="bold"/>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Placebo</content>
                                                </paragraph>
                                                <paragraph>
                                                   <content styleCode="bold">(N = 162)</content>
                                                   <footnoteRef IDREF="_Ref191881953"/>
                                                   <content styleCode="bold"/>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">In combination with Dapagliflozin and Metformin HCl</content>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>
                                                   <content styleCode="bold">Hemoglobin A1C (%)</content>
                                                   <footnote ID="_Ref191881988">Analysis of Covariance including all post-baseline data regardless of rescue or treatment discontinuation. Model estimates calculated using multiple imputation to model washout of the treatment effect using placebo data for all patients having missing Week 24 data.</footnote>
                                                </paragraph>
                                             </td>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                             <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Baseline (mean)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>8.0</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>7.9</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Change from baseline (adjusted mean<footnote ID="_Ref191882015">Least squares mean adjusted for baseline value.</footnote>) </paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.2</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.6, -0.4)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>(-0.3, -0.1)</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Lrule Botrule " valign="top">
                                                <paragraph>Difference from placebo (adjusted mean)</paragraph>
                                             </td>
                                             <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                                <paragraph>-0.4<footnote ID="_Ref191882029">p-value &lt; 0.0001.</footnote>
                                                </paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>Â Â Â 95% Confidence Interval</paragraph>
                                             </td>
                                             <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                                <paragraph>(-0.5, -0.2)</paragraph>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>The known proportion of patients achieving HbA1c &lt; 7% at Week 24 was 35.3% in the saxagliptin-treated group compared to 23.1% in the placebo-treated group.</paragraph>
                                 </text>
                                 <effectiveTime value="20250228"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_bf75c661-841c-4a69-8df6-66385f6c3e24">
                     <id root="d7ccdf17-51e2-4e83-a133-d4cc358e5ff2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Renal Impairment </title>
                     <text>
                        <paragraph>A total of 170 patients participated in a 12-week, randomized, double-blind, placebo-controlled trial conducted to evaluate the efficacy and safety of saxagliptin tablets 2.5 mg once daily compared with placebo in patients with type 2 diabetes mellitus and moderate (n = 90) or severe (n = 41) renal impairment or ESRD (n = 39). In this trial, 98% of the patients were using background antidiabetic medications (75% were using insulin and 31% were using oral antidiabetic medications, mostly sulfonylureas).</paragraph>
                        <paragraph>After 12 weeks of treatment, saxagliptin tablets 2.5 mg provided significant improvement in A1C compared to placebo (Table 13). In the subgroup of patients with ESRD, saxagliptin tablets and placebo resulted in comparable reductions in A1C from baseline to Week 12. This finding is inconclusive because the trial was not adequately powered to show efficacy within specific subgroups of renal impairment.</paragraph>
                        <paragraph>After 12 weeks of treatment, the mean change in FPG was -12 mg/dL with saxagliptin tablets 2.5 mg and -13 mg/dL with placebo. Compared to placebo, the mean change in FPG with saxagliptin tablets was -12 mg/dL in the subgroup of patients with moderate renal impairment, -4 mg/dL in the subgroup of patients with severe renal impairment, and +44 mg/dL in the subgroup of patients with ESRD. These findings are inconclusive because the trial was not adequately powered to show efficacy within specific subgroups of renal impairment.</paragraph>
                        <table width="100%">
                           <caption>Table 13: A1C at Week 12 in a Placebo-Controlled Trial of Saxagliptin Tablets in Patients with Renal Impairment<footnote ID="_Ref527024510">Intent-to-treat population using last observation on trial.</footnote>
                           </caption>
                           <col width="54%"/>
                           <col width="23%"/>
                           <col width="22%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Efficacy Parameter</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Saxagliptin Tablets</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">2.5 mg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 85</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 85</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Hemoglobin A1C (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">N = 81</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">N = 83</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Â Â Â Baseline (mean)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>8.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>8.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Â Â Â Change from baseline (adjusted mean<footnote ID="_Ref527024518">Least squares mean adjusted for baseline value.</footnote>)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-0.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Â Â Â Difference from placebo (adjusted mean<footnoteRef IDREF="_Ref527024518"/>)</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-0.4<footnote ID="_Ref527024535">p-value &lt; 0.01 compared to placebo.</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Â Â Â Â Â Â 95% Confidence Interval</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>(-0.7, -0.1)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a58c01cc-8043-4438-9540-b933d47e790e">
                     <id root="e113d7b7-0a7f-4d98-9a26-70c0a45f53a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3	Cardiovascular Safety Trial </title>
                     <text>
                        <paragraph>The cardiovascular risk of saxagliptin tablets was evaluated in SAVOR, a multicenter, multinational, randomized, double-blind trial comparing saxagliptin tablets (N = 8280) to placebo (N = 8212), both administered in combination with standard of care, in adult patients with type 2 diabetes mellitus at high risk for atherosclerotic cardiovascular disease. Of the randomized trial patients, 97.5% completed the trial, and the median duration of follow-up was approximately 2 years. The trial was event-driven, and patients were followed until a sufficient number of events were accrued.</paragraph>
                        <paragraph>Patients were at least 40 years of age, had A1C â¥ 6.5%, and multiple risk factors (21% of randomized patients) for cardiovascular disease (age â¥ 55 years for men and â¥ 60 years for women plus at least one additional risk factor of dyslipidemia, hypertension, or current cigarette smoking) or established (79% of the randomized patients) cardiovascular disease defined as a history of ischemic heart disease, peripheral vascular disease, or ischemic stroke. Overall, the use of diabetes medications was balanced across treatment groups (metformin HCl 69%, insulin 41%, sulfonylureas 40%, and TZDs 6%). The use of cardiovascular disease medications was also balanced [angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) 79%, statins 78%, aspirin 75%, beta-blockers 62%, and non-aspirin antiplatelet medications 24%].</paragraph>
                        <paragraph>The majority of patients were male (67%) and White (75%) with a mean age of 65 years. Approximately 16% of the population had moderate (estimated glomerular filtration rate [eGFR] â¥ 30 to â¤ 50 mL/min/1.73 m<sup>2</sup>) to severe (eGFR &lt; 30 mL/min/1.73 m<sup>2</sup>) renal impairment, and 13% had a prior history of heart failure. Patients had a median duration of type 2 diabetes mellitus of approximately 10 years, and a mean baseline A1C level of 8.0%. Approximately 5% of patients were treated with diet and exercise only at baseline. Overall, the use of diabetes medications was balanced across treatment groups (metformin HCl 69%, insulin 41%, sulfonylureas 40%, and TZDs 6%). The use of cardiovascular disease medications was also balanced (ACE inhibitors or ARBs 79%, statins 78%, aspirin 75%, beta-blockers 62%, and non-aspirin antiplatelet medications 24%).</paragraph>
                        <paragraph>The primary analysis in SAVOR was time to first occurrence of a Major Adverse Cardiac Event (MACE). A major adverse cardiac event in SAVOR was defined as a cardiovascular death or a nonfatal myocardial infarction (MI) or a nonfatal ischemic stroke. The trial was designed as a non-inferiority trial with a pre-specified risk margin of 1.3 for the hazard ratio of MACE and was also powered for a superiority comparison if non-inferiority was demonstrated.</paragraph>
                        <paragraph>The results of SAVOR, including the contribution of each component to the primary composite endpoint, are shown in Table 14. The incidence rate of MACE was similar in both treatment arms: 3.8 MACE per 100 patient-years on placebo vs. 3.8 MACE per 100 patient-years on saxagliptin tablets. The estimated hazard ratio of MACE associated with saxagliptin tablets relative to placebo was 1.00 with a 95.1% confidence interval of (0.89, 1.12). The upper bound of this confidence interval, 1.12, excluded a risk margin larger than 1.3.</paragraph>
                        <table width="100%">
                           <caption>Table 14: Major Adverse Cardiovascular Events (MACE) by Treatment Group in the SAVOR Trial</caption>
                           <col width="28%"/>
                           <col width="16%"/>
                           <col width="13%"/>
                           <col width="16%"/>
                           <col width="13%"/>
                           <col width="14%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Saxagliptin Tablets</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Hazard <br/>Ratio</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Number of Patients (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rate per 100 PY</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Number of Patients (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rate per 100 PY</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">(95.1% CI)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Composite of first event of CV death, non-fatal MI or non-fatal ischemic stroke (MACE)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">N = 8280</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Total PY = 16308.8</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">N = 8212</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Total PY = 16156.0</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>613 (7.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>609 (7.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.00</paragraph>
                                    <paragraph>(0.89, 1.12)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Â Â Â CV death</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>245 (3.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>234 (2.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.4</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Â Â Â Non-fatal MI</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>233 (2.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>260 (3.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.6</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Â Â Â Non-fatal ischemic stroke</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>135 (1.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>115 (1.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0.7</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The Kaplan-Meier-based cumulative event probability is presented in Figure 2 for time to first occurrence of the primary MACE composite endpoint by treatment arm. The curves for both saxagliptin tablets and placebo arms are close together throughout the duration of the trial. The estimated cumulative event probability is approximately linear for both arms, indicating that the incidence of MACE for both arms was constant over the trial duration.</paragraph>
                        <renderMultiMedia ID="id-1713951744" referencedObject="ID_48d928c6-4a08-410c-9a66-a448bf948c68">
                           <caption>Figure 2: Cumulative Percent of Time to First MACE</caption>
                        </renderMultiMedia>
                        <paragraph>Vital status was obtained for 99% of patients in the trial. There were 798 deaths in the SAVOR trial. Numerically more patients (5.1%) died in the saxagliptin tablets group than in the placebo group (4.6%). The risk of deaths from all cause (Table 15) was not statistically different between the treatment groups (HR: 1.11; 95.1% CI: 0.96, 1.27). </paragraph>
                        <table width="100%">
                           <caption>Table 15: All-cause mortality by Treatment Group in the SAVOR Trial</caption>
                           <col width="28%"/>
                           <col width="16%"/>
                           <col width="13%"/>
                           <col width="16%"/>
                           <col width="13%"/>
                           <col width="14%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Saxagliptin Tablets</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Hazard Ratio</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Number of<br/>Patients (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rate per<br/>100 PY</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Number of<br/>Patients (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rate per <br/>100 PY</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">(95.1% CI)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">N = 8280</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">PY = 16645.3</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">N = 8212</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">PY = 16531.5</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">All-cause mortality</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>420 (5.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>378 (4.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.11</paragraph>
                                    <paragraph>(0.96, 1.27)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Â Â Â CV death</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>269 (3.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>260 (3.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.6</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Â Â Â Non-CV death</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>151 (1.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>118 (1.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0.7</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250228"/>
                     <component>
                        <observationMedia ID="ID_48d928c6-4a08-410c-9a66-a448bf948c68">
                           <text>Figure 2: Cumulative Percent of Time to First MACE</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="image-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3d783323-bea8-41f3-83f0-241977488f31">
               <id root="670116d4-513c-4e6a-b621-4412f1d7d7e0"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">How Supplied</content>
                  </paragraph>
                  <paragraph>Saxagliptin Tablets are available containing 3.075 mg or 6.149 mg of saxagliptin hydrochloride dihydrate equivalent to 2.5 mg or 5 mg of saxagliptin.</paragraph>
                  <paragraph>The 2.5 mg tablets are yellow, film-coated, round, unscored tablets imprinted with <content styleCode="bold">SX1</content> over <content styleCode="bold">M </content>in black ink on one side of the tablet and blank on the other side. They are available as follows:</paragraph>
                  <paragraph>NDC 0378-4705-93<br/>bottles of 30 tablets</paragraph>
                  <paragraph>NDC 0378-4705-77<br/>bottles of 90 tablets</paragraph>
                  <paragraph>The 5 mg tablets are white to off-white, film-coated, round, unscored tablets imprinted with <content styleCode="bold">SX2</content> over <content styleCode="bold">M </content>in black ink on one side of the tablet and blank on the other side. They are available as follows:</paragraph>
                  <paragraph>NDC 0378-4706-93<br/>bottles of 30 tablets</paragraph>
                  <paragraph>NDC 0378-4706-77<br/>bottles of 90 tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage and Handling</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.] </content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST:</content> Dispense a Medication Guide with each prescription.</paragraph>
               </text>
               <effectiveTime value="20250228"/>
            </section>
         </component>
         <component>
            <section ID="ID_cd687a72-336e-4f1b-8241-d49e2340b47e">
               <id root="78b87095-17cb-41ae-a933-b8ca3f1ac450"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pancreatitis</content>
                  </paragraph>
                  <paragraph>Inform patients that acute pancreatitis has been reported during postmarketing use of saxagliptin tablets. Educate patients that persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting, is the hallmark symptom of acute pancreatitis. Instruct patients to promptly discontinue saxagliptin tablets and contact their health care provider if persistent severe abdominal pain occurs [<content styleCode="italics">see <linkHtml href="#ID_6fd8cfc7-89d8-4016-bdd4-141f7d5d3b8f">Warnings and Precautions (5.1)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="underline">Heart Failure</content>
                  </paragraph>
                  <paragraph>Inform patients of the signs and symptoms of heart failure. Before initiating saxagliptin tablets, ask patients if they have a history of heart failure or other risk factors for heart failure including moderate to severe renal impairment. Instruct patients to contact their health care provider as soon as possible if they experience symptoms of heart failure, including increasing shortness of breath, rapid increase in weight or swelling of the feet [<content styleCode="italics">see <linkHtml href="#ID_5e9d776f-8f20-4110-910e-ccb6ef554034">Warnings and Precautions (5.2)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues</content>
                  </paragraph>
                  <paragraph>Inform patients that hypoglycemia can occur, particularly when insulin or an insulin secretagogue is used in combination with saxagliptin tablets. Educate patients about the risks, symptoms and appropriate management of hypoglycemia [<content styleCode="italics">see <linkHtml href="#ID_e5fc6b8e-d5f7-4aa6-a1c8-bb81dd5f1b30">Warnings and Precautions (5.3)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Patients should be informed that serious allergic (hypersensitivity) reactions, such as angioedema, anaphylaxis, and exfoliative skin conditions, have been reported during postmarketing use of saxagliptin tablets. If symptoms of these allergic reactions (such as rash, skin flaking or peeling, urticaria, swelling of the skin, or swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing) occur, patients must stop taking saxagliptin tablets and seek medical advice promptly [<content styleCode="italics">see <linkHtml href="#ID_8c98972f-67eb-45e1-87ae-a7840ea32027">Warnings and Precautions (5.4)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="underline">Severe and Disabling Arthralgia</content>
                  </paragraph>
                  <paragraph>Inform patients that severe and disabling joint pain may occur with this class of drugs. The time to onset of symptoms can range from one day to years. Instruct patients to seek medical advice if severe joint pain occurs [<content styleCode="italics">see <linkHtml href="#ID_b0ec0aa9-80d4-4a6a-9c30-0807d5ed49c8">Warnings and Precautions (5.5)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="underline">Bullous Pemphigoid</content>
                  </paragraph>
                  <paragraph>Inform patients that bullous pemphigoid may occur with this class of drugs. Instruct patients to seek medical advice if blisters or erosions occur [<content styleCode="italics">see <linkHtml href="#ID_09a99408-1947-4d2a-9445-3c5aca5a5ba2">Warnings and Precautions (5.6)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="underline">Missed Dose</content>
                  </paragraph>
                  <paragraph>If a dose is missed, advise patients to take saxagliptin tablets as soon as they remember unless it is time for their next dose. Instruct patients not to take two doses of saxagliptin tablets at the same time.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients not to cut, crush, or chew saxagliptin tablets.</paragraph>
               </text>
               <effectiveTime value="20250228"/>
            </section>
         </component>
         <component>
            <section ID="ID_f7c5df57-401b-4269-90c4-7b43f53b8583">
               <id root="405e4f71-537d-4636-b6d4-6bf529d94878"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>Medication Guide </title>
               <text>
                  <table width="100%">
                     <col width="20%"/>
                     <col width="26%"/>
                     <col width="30%"/>
                     <col width="23%"/>
                     <tbody>
                        <tr>
                           <td colspan="4" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Saxagliptin Tablets, for oral use</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(saxâ³ a glipâ² tin)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about saxagliptin tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Serious side effects can happen to people taking saxagliptin tablets, including:</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>1.</caption>
                                    <content styleCode="bold">Inflammation of the pancreas (pancreatitis)</content> which may be severe and lead to death. </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                              </paragraph>
                              <paragraph>Certain medical problems make you more likely to get pancreatitis.</paragraph>
                              <paragraph>Â </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Before you start taking saxagliptin tablets:</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                              </paragraph>
                              <paragraph>Tell your healthcare provider if you have ever had:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>inflammation of your pancreas (pancreatitis)</item>
                                 <item>
                                    <caption>â¢</caption>a history of alcoholism</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>stones in your gallbladder (gallstones)</item>
                                 <item>
                                    <caption>â¢</caption>high blood triglyceride levels</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Â Stop taking saxagliptin tablets and contact your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen through to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis.</paragraph>
                              <paragraph>Â </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>2.</caption>
                                    <content styleCode="bold">Heart failure. </content>Heart failure means your heart does not pump blood well enough.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Before you start taking saxagliptin tablets:</content>
                              </paragraph>
                              <paragraph>Tell your healthcare provider if you:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>have ever had heart failure or have problems with your kidneys.</item>
                              </list>
                              <paragraph>Contact your healthcare provider right away if you have any of the following symptoms: </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>increasing shortness of breath or trouble breathing, especially when you lie down</item>
                                 <item>
                                    <caption>â¢</caption>swelling or fluid retention, especially in the feet, ankles or legs</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>an unusually fast increase in weight</item>
                                 <item>
                                    <caption>â¢</caption>unusual tiredness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>These may be symptoms of heart failure.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are saxagliptin tablets?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>Saxagliptin tablets are a prescription medicine used along with diet and exercise to help control high blood sugar in adults with type 2 diabetes mellitus.</item>
                                 <item>
                                    <caption>â¢</caption>Saxagliptin tablets are not recommended for people with type 1 diabetes mellitus.</item>
                                 <item>
                                    <caption>â¢</caption>Saxagliptin tablets are not recommended for people with diabetic ketoacidosis (increased ketones in your blood or urine).</item>
                              </list>
                              <paragraph>It is not known if saxagliptin tablets are safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Who should not take saxagliptin tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not take saxagliptin tablets if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>are allergic to any ingredients in saxagliptin tablets. See the end of this Medication Guide for a complete list of ingredients in saxagliptin tablets.</item>
                              </list>
                              <paragraph>Symptoms of a serious allergic reaction to saxagliptin tablets may include:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>swelling of your face, lips, throat, and other areas on your skin</item>
                                 <item>
                                    <caption>â¢</caption>raised, red areas on your skin (hives)</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>difficulty with swallowing or breathing</item>
                                 <item>
                                    <caption>â¢</caption>skin rash, itching, flaking, or peeling</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>If you have these symptoms, stop taking saxagliptin tablets and contact your healthcare provider right away.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before taking saxagliptin tablets, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>have heart failure</item>
                                 <item>
                                    <caption>â¢</caption>have or have had inflammation of your pancreas (pancreatitis) </item>
                                 <item>
                                    <caption>â¢</caption>have kidney problems.</item>
                                 <item>
                                    <caption>â¢</caption>are pregnant or plan to become pregnant. It is not known if saxagliptin tablets will harm your unborn baby. If you are pregnant, talk with your healthcare provider about the best way to control your blood sugar while you are pregnant.</item>
                                 <item>
                                    <caption>â¢</caption>are breastfeeding or plan to breastfeed. Saxagliptin may be passed in your milk to your baby. Talk with your healthcare provider about the best way to feed your baby while you take saxagliptin tablets.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>Â </paragraph>
                              <paragraph>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                              <paragraph>Â </paragraph>
                              <paragraph>Saxagliptin tablets may affect the way other medicines work, and other medicines may affect how saxagliptin tablets work. Contact your healthcare provider if you will be starting or stopping certain other types of medicines, such as antibiotics, or medicines that treat fungus or HIV/AIDS, because your dose of saxagliptin tablets might need to be changed.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I take saxagliptin tablets?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>Take saxagliptin tablets by mouth 1 time each day exactly as directed by your healthcare provider. Do not change your dose without talking to your healthcare provider.</item>
                                 <item>
                                    <caption>â¢</caption>Saxagliptin tablets can be taken with or without food.</item>
                                 <item>
                                    <caption>â¢</caption>Do not cut, crush, or chew saxagliptin tablets.</item>
                                 <item>
                                    <caption>â¢</caption>Your healthcare provider should test your blood to measure how well your kidneys are working before and during your treatment with saxagliptin tablets. You may need a lower dose of saxagliptin tablets if your kidneys are not working well.</item>
                                 <item>
                                    <caption>â¢</caption>If you miss a dose of saxagliptin tablets, just take the next dose at your regular time. Do not take two doses at the same time.</item>
                                 <item>
                                    <caption>â¢</caption>In case of an overdose contact the Poison Help line at 1-800-222-1222 or get medical help right away. Advice is also available online at poisonhelp.org.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of saxagliptin tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Saxagliptin tablets can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>See â<content styleCode="bold">What is the most important information I should know about saxagliptin tablets?</content>â</item>
                                 <item>
                                    <caption>â¢</caption>
                                    <content styleCode="bold">Low blood sugar (hypoglycemia).</content> If you take saxagliptin tablets with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take saxagliptin tablets. Symptoms of low blood sugar include:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>shaking</item>
                                 <item>
                                    <caption>o</caption>hunger</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>sweating</item>
                                 <item>
                                    <caption>o</caption>headache</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>rapid heartbeat</item>
                                 <item>
                                    <caption>o</caption>change in mood</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>change in vision</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>
                                    <content styleCode="bold">Allergic (hypersensitivity) reactions</content>, such as:<list listType="unordered">
                                       <item>
                                          <caption>o</caption>swelling of your face, lips, throat, and other areas on your skin</item>
                                       <item>
                                          <caption>o</caption>difficulty with swallowing or breathing</item>
                                       <item>
                                          <caption>o</caption>raised, red areas on your skin (hives)</item>
                                       <item>
                                          <caption>o</caption>skin rash, itching, flaking, or peeling</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>Â </caption>If you have these symptoms, stop taking saxagliptin tablets and contact your healthcare provider right away.</item>
                              </list>
                              <paragraph>Â </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>
                                    <content styleCode="bold">Joint pain.</content> Some people who take medicines called DPP-4 inhibitors like saxagliptin tablets, may develop joint pain that can be severe. Call your healthcare provider if you have severe joint pain.</item>
                                 <item>
                                    <caption>â¢</caption>
                                    <content styleCode="bold">Skin reaction.</content> Some people who take medicines called DPP-4 inhibitors, like saxagliptin tablets, may develop a skin reaction called bullous pemphigoid that can require treatment in a hospital. Tell your healthcare provider right away if you develop blisters or the breakdown of the outer layer of your skin (erosion). Your healthcare provider may tell you to stop taking saxagliptin tablets.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of saxagliptin tablets include:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>upper respiratory tract infection</item>
                                 <item>
                                    <caption>â¢</caption>urinary tract infection</item>
                                 <item>
                                    <caption>â¢</caption>headache</item>
                                 <item>
                                    <caption>â¢</caption>swelling or fluid retention in your hands, feet, or ankles (peripheral edema) may become worse in people who also take a thiazolidinedione to treat diabetes. If you do not know whether you are already on this type of medication, ask your healthcare provider.</item>
                              </list>
                              <paragraph>These are not all of the possible side effects of saxagliptin tablets. </paragraph>
                              <paragraph>Â </paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I store saxagliptin tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                              </paragraph>
                              <paragraph>Store saxagliptin tablets between 20Â° to 25Â°C (68Â° to 77Â°F).</paragraph>
                              <paragraph>Â </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Keep saxagliptin tablets and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the use of saxagliptin tablets</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use saxagliptin tablets for a condition for which they were not prescribed. Do not give saxagliptin tablets to other people, even if they have the same symptoms you have. They may harm them.</paragraph>
                              <paragraph>Â </paragraph>
                              <paragraph>You can ask your healthcare provider for additional information about saxagliptin tablets that is written for health professionals. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients of saxagliptin tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> saxagliptin</paragraph>
                              <paragraph>Â </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> croscarmellose sodium, hydrochloric acid, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium hydroxide, talc and titanium dioxide. The 2.5 mg tablets also contain yellow iron oxide. The imprinting ink contains ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505</paragraph>
                              <paragraph>Manufactured by: Mylan Laboratories Limited, Hyderabad â 500 096, India</paragraph>
                              <paragraph>Â </paragraph>
                              <paragraph>For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX).</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Mylan Pharmaceuticals Inc.<br/>
                     </content>Morgantown, WV  26505  U.S.A.</paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">Mylan Laboratories Limited<br/>
                     </content>Hyderabad â 500 096, India</paragraph>
                  <paragraph>75108321</paragraph>
                  <paragraph>Revised: 2/2025<br/>MXA:SAXA:R2m/MXA:MG:SAXA:R2m</paragraph>
               </text>
               <effectiveTime value="20250228"/>
            </section>
         </component>
         <component>
            <section ID="ID_8bac2f3a-6784-4a94-8490-3c8cb3a43812">
               <id root="d8f56d28-732e-426b-9bfb-60d8dd9b50e7"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL â 2.5 mg </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 0378-4705-93</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Saxagliptin<br/>Tablets<br/>2.5 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST: Dispense the accompanying<br/>Medication Guide to each patient.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx onlyÂ Â Â 30 Tablets</content>
                  </paragraph>
                  <paragraph>Each film-coated tablet contains<br/>3.075 mg of saxagliptin hydrochloride<br/>dihydrate equivalent to 2.5 mg of<br/>saxagliptin.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Usual Dosage:</content> See accompanying<br/>prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep this and all medication out of<br/>the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See<br/>USP Controlled Room Temperature.]</content>
                  </paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Mylan Pharmaceuticals Inc.</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>Made in India</paragraph>
                  <paragraph>
                     <content styleCode="bold">Mylan.com</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">RMXA4705H2</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant<br/>container as defined in the USP<br/>using a child-resistant closure.</paragraph>
                  <paragraph>Keep container tightly closed.</paragraph>
                  <paragraph>Code No.: MH/DRUGS/AD/089</paragraph>
                  <renderMultiMedia ID="id-1912378870" referencedObject="FD728427-780C-4DB5-BEEB-5FA649E1DA40"/>
               </text>
               <effectiveTime value="20230423"/>
               <component>
                  <observationMedia ID="FD728427-780C-4DB5-BEEB-5FA649E1DA40">
                     <text>Saxagliptan Tablets 2.5 mg Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c7f0a0a3-75b1-4d45-8e8f-0f05ca3c3acc">
               <id root="0f0a9bf5-d97e-4f89-a3fd-e19dbfb27548"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL â 5 mg </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 0378-4706-93</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Saxagliptin<br/>Tablets<br/>5 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST: Dispense the accompanying<br/>Medication Guide to each patient.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx onlyÂ Â Â 30 Tablets</content>
                  </paragraph>
                  <paragraph>Each film-coated tablet contains<br/>6.149 mg of saxagliptin hydrochloride<br/>dihydrate equivalent to 5 mg of<br/>saxagliptin.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Usual Dosage:</content> See accompanying<br/>prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep this and all medication out of<br/>the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See<br/>USP Controlled Room Temperature.]</content>
                  </paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Mylan Pharmaceuticals Inc.</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>Made in India</paragraph>
                  <paragraph>
                     <content styleCode="bold">Mylan.com</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">RMXA4706H2</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant<br/>container as defined in the USP<br/>using a child-resistant closure.</paragraph>
                  <paragraph>Keep container tightly closed.</paragraph>
                  <paragraph>Code No.: MH/DRUGS/AD/089</paragraph>
                  <renderMultiMedia ID="id1725179582" referencedObject="FB888399-A350-44CF-B4B6-8EE1439B5FF2"/>
               </text>
               <effectiveTime value="20230423"/>
               <component>
                  <observationMedia ID="FB888399-A350-44CF-B4B6-8EE1439B5FF2">
                     <text>Saxagliptan Tablets 5 mg Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>